



06.09.2023 .

	(/)		400
A06.30.002.001			1000
	(, , ,)		200
	(, ,)		350
A06.30.002.002			1000
A06.30.002			500
B01.039.001	(,) -		1200
B01.039.002	(,) -		1100
A06.23.004	/		2600
A06.23.005.006	/		8700
A06.08.007	,		2600
A06.08.007.004			8700
A06.25.003			2600
A06.25.003.002			8700
A06.26.006			2600
A06.26.006.001			8700
A06.23.004.007			8700
A06.08.007.002			8700
			8700
A06.08.009.002			8700
A06.09.005			2600
A06.09.005.002			8700
A06.11.004			2600
A06.11.004.001			8700
A06.30.005			3500
A06.30.005.003			8700

A06.28.009						3500
A06.28.009.001						8700
A06.30.007						8700
A06.30.007.002						8700
A06.30.005.001						8700
-	()				
A06.03.021.001						2600
A06.03.021.002						8700
A06.03.021.001		-	2	(2		3600
,2	,2)				
A06.03.021.002		-	2	(2		9700
,2	,2)				
A06.03.036.001						2600
A06.03.036.002						8700
A06.03.058		()			2600
A06.03.058.003	()				8700
A06.03.062						2600
A06.04.020		-				2600
A06.04.017						2600
						2600
						8700
A06.12.052	-					8700
A06.12.053	-					8700
A06.12.050	-					8700
A06.12.054	-					8700
A06.12.055	-					8700
A06.12.057	-					8700
A06.12.058	-					8700
A06.12.001.001	-					8700
A06.12.001.002	-					8700
A06.10.009		()			3500
A06.10.006.001	-					8700
A06.10.006.001						8700
-						
A05.23.009						3100
A05.23.009.001						7100
A05.12.004	()				3100
A05.12.005	()				3100
						7100
						7100

A05.22.002.001		6500
A05.26.008.001		7100
A05.08.001		3100
A05.26.008		3100
A05.22.002		3100
A05.04.001	-	5000
A05.30.008		3100

A05.04.001	-	3100
A05.30.008		3100
A05.03.002		3100
A05.03.002		3100
A05.03.002		3100
A05.03.002.001		7100
A05.30.008.001		7100
A05.03.002.001		7100
A05.03.002.001		7100
A05.23.009.010	()	3100
A05.23.009.011	()	7100

	()	14000
A05.30.005		4000
A05.30.007		4000
A05.30.005.001		7100
A05.30.007.001		7100
A05.22.001	-	4000
A05.22.001.001	-	7100
A05.14.002		7100
A05.15.001		3500
A05.15.002		4000
A05.28.002		3100

A05.30.004.001		7100
A05.30.004		4000
A05.21.001		4000
	()+	7000
A05.21.001.001	c	7100

A05.30.004.001		7100
A05.30.004		4000

A05.30.004	() (, ,)	4000
------------	-------------	------

A05.04.001	(, ,) , , ,	3500
------------	---------------	------

A05.30.011.002		3500		
A05.30.012.002		3500		
A05.30.010		4000		
A05.01.002		4000		
A05.01.001		7100		
A05.30.010.001		7100		
A05.03.002	+	+	7000	
	+		5000	
	+		5000	
	+		5000	
	:	+	+	7000
	+	+		7000
	+			4500
	+			4500
		+		5000
A05.03.002		+		4500
		+		4500
	+			7000
	+			4500
		+		4500
		+		5000
A06.08.003			800	
			800	
	2		800	
A06.08.003.002			800	
A06.08.003.002			800	
A06.03.005		,	800	
A06.03.056			800	
A06.04.001		-	800	
A06.26.001			800	
A06.07.008			800	
A06.07.009			800	
A06.25.002			800	
A06.25.002.001			800	
A06.03.010			800	
()	3		1000	
A06.03.013			800	
A06.03.019			1600	

A06.03.014			1600
-			
A06.03.015		2	800
		3	1000
A06.03.017			800
A06.03.016			1600
A06.03.017.001			800
A06.03.017.002			800
-			
A06.04.013		-	800
		2	800
A06.04.010			800
A06.03.028			800
A06.04.003			800
A06.03.029			800
A06.04.004			800
A06.03.026			800
A06.03.032			800
		2	800
A06.03.035		1	700
A06.03.021			800
A06.03.030			800
A06.03.027			800
A06.03.031			800
A06.03.033			700
-			
A06.04.005			800
		2	(1)
		2	700
			850
A06.03.042			850
		2	800
A06.04.012			800
A06.03.053		2	800
			800
A06.03.050			800
			700
			2
			1600
A06.03.036			800
A06.03.048			800
A06.03.054			800
A06.03.055		1	700
A06.04.011			800
A06.03.043			800
A06.03.045			800
A06.03.046			800

A06.03.049						800
A06.03.051						800
A06.03.052		1				800
A06.03.053.001						800
A06.30.004.001						700
						3000
A06.28.001						800
		2				800
A06.28.002						3100
		1	()			700
		2				850
A06.03.023		()				800
A06.03.024						800
A06.04.014		-				800
A06.03.022						700
A06.09.007						800
		-				800
						700
		1				700
		2				800
A06.20.004						1000
A06.20.004		2				1500
	c		(1	2-)	1500
	c		(2	2-)	2500
A06.20.004.002						1500
A06.20.008						1000
B01.023.001	(,)	-				1200
B01.023.002	(,)	-				1100
B01.023.001	(,)					2500
(-)						
B01.023.001	(,)	-	()	60		2300
B01.023.002	(,)	-	()	30		2100
A11.02.002	(1)					2500
A22.30.015	(1)					1000
A11.02.002						29900
A25.24.001.002						19500
A25.24.001.002						8900
A11.01.002		225	()			24000

A11.24.001			2000
A11.02.002			1500
A11.02.002			1500
A11.02.002	()	1500

B01.047.001	(,)	-	1000
B01.047.002	(,)	-	1100
	()			1200
	()			2500

B01.031.001	()			1200		
B01.031.002	()			1100		
B01.031.001	()			2000		
B01.031.002	()			2000		
B01.031.001					1200		
B01.031.001	()			1200		
B01.031.001			-1	(,)	1500
B01.031.001	()			800		
B01.031.001	/	()		700		
B01.031.001	(:	,)	800		
B01.031.001			18	(095/)	800
-	095/				800		
B01.031.001					800		
B01.031.001	-	(076/)	2000		
B01.031.001		(079/)??	800		

B01.029.001	(,)	-	1200
B01.029.002	(,)	-	1100

A02.26.015	-	()	200
A12.26.016				150
A03.26.010		()	400
A03.26.010		()	400
A02.26.015				200
A02.26.015	()		400
A02.26.015	()		200

B01.057.001	(,)	-	1200
B01.057.002	(,)	-	1100

B01.057.001	(,)	-	(800
B01.057.002	(,)		()	800
A16.01.012.001				1900
A16.01.012				1200
A16.01.002				1500
A16.01.002				1200
A16.01.012.001	()	()	2	1800
A16.01.011	()			1000
A16.01.027				2600
A16.30.060				1800
A16.01.009	()			1500
A16.30.069	()			500
A16.01.001				1000
A11.04.005				1000
A16.01.012.001				1300
A11.30.024				1100
A16.01.012.001	()	()	1	1300
A16.01.008.001				2100
A16.01.004			(700
A16.01.004			()	2000
A15.01.001				400
A15.01.002				500
A11.01.001	()			400
A16.30.076				1400
A16.01.028	()			500
A16.01.016	(0,5-1 ,1)			1300
A16.01.016	(1-3 ,1)			1500
A16.01.016	(3-5 ,1)			1900
A16.01.017			(1-3 ,1)	1300
A16.01.017			(3-5 ,1)	1500
A16.01.017			(3-5 ,1)	1900
A16.01.017			(5 ,1)	2400
				500
A16.01.018			-	1300
(, , 0,5-1 -1)				1300
A16.01.018			-	1500
(, , 1-3 -1)				1500
B01.003.004.005				500
B01.003.004.001				500
A11.01.001	()			400
A16.01.003				2000
A16.30.032		1 -3	1	1300
A16.30.032		3 -5	1	1900
A16.01.018			-	1900
(, , 3 -5 1)				1900

A16.30.007.001				19000	
A16.30.043.002				14800	
A16.30.043.003				26000	
A16.14.018.003				11000	
A16.30.004.003		()	42300	
				56400	
A16.30.004.007				65000	
A16.30.004.016				55000	
A16.01.018			-	6500	
(5	1)		
A16.30.001.002			-	35000	
A16.30.002.002				35000	
A16.30.001		()	23100	
A16.30.002		()	20000	
A16.14.009.002				35000	
A16.19.018			()	15000
A16.30.032		5	1	6500	
A16.30.004.004			()	46000
A16.30.004.010			1	40000	
A16.30.004.010			2	55000	
A16.30.004.010			3	70000	
A04.12.005.003			()	1500
-		(+)	2400
-		(+)	2800
				1500	
A04.12.001.004			-	800	
A04.12.001.004				800	
A04.12.001.001				1400	
A04.12.002.002				1400	
A04.12.002.001				2000	
A04.12.002				1900	
A04.12.002.003				1000	
A04.12.001				1000	
		()	+	2000
A04.12.014				900	
A04.12.001.006			()	1800
		()	+	2800
A04.12.022				1400	
A04.12.001.002				700	

A04.20.002		950
		1100
A04.30.010 ()		950
A04.30.001) (1000
A04.30.001.001 ()		1000
A04.30.001.007 III		1500
A04.12.024.003 II-III) (1000
A04.04.001 ()		700
A04.20.003 ()		700
A04.20.003 ()		400
A04.20.001.004 (-)		500
A04.30.001.002 , ,1) 4D (26 ,		2500
A04.30.001 II		1200
A04.30.001.002 3D		1350
A04.30.001.001 ()		1500
A04.12.024.003) () (II-III) (1500
A04.30.001.006 - , , , (II)		2000
A04.30.001.008 III		2000
A04.30.001.002 (26 , , 4D ,1)		3500
A04.30.001.002 3D		2000
A11.06.001.001		900
A11.20.010.003		900
A11.22.002.001		900
A11.30.024.001		900
A04.04.001 ()1		900
A04.04.001 ()1		700
A04.04.001 ()1		800
A04.04.001 ()1		800
A04.04.001 ()1		800
A04.04.001 ()1		800
A04.04.001 ()1		600
A04.04.002 ()		600
B03.037.001		500
A05.10.006		500

A02.12.002.001		1200
A05.10.008	24	2000
+	24	2200
A12.10.001 ()	+	750
		750
		150
	: , ()	420
	: , (« »)	590
	() ()	190
	:	3230
	:	2020
	:	1100
B03.005.006 () ,		770
()		2510
	(HIV, Syphilis, Hepatitis B, C)	1400
	IgG	470
	IgG	470
(Coronavirus disease 2019, COVID-19)		
	SARS-CoV-2 () , IgG, (Anti-SARS-CoV-2 (nucleocapsid protein), IgG, Abbott)	690
	SARS-CoV-2, IgM (anti-SARS-CoV-2, IgM)	690
	SARS-CoV-2, IgM IgG (. . . IgG - Abbott)	1290
	(S) SARS-CoV-2, IgG () , . . . (anti-SARS-CoV-2 S (spike) protein antibody, IgG, qual., including post-vaccination)	890
	SARS-CoV-2 (RBD), IgG (anti-SARS-CoV-2 (RBD) IgG avidity)	690
	SARS CoV-2 (S- , RBD), IgG, -	1290
	SARS CoV-2 (S- , RBD), IgG, Abbott	1290
	SARS-CoV-2, IgM () IgG () (Anti-SARS-CoV-2, IgM/IgG)	1690
	SARS-CoV-2, IgM () IgG () (Anti-SARS-CoV-2, IgM/IgG)	1690
A	IgG Helicobacter pylori (Anti-Helicobacter pylori IgG)	490
	. (UROGENITAL TRACT MICROBIOCENOSIS, Screening (PCR Panel Femoflor Screen))	1850
	- , ()	
	, o 4 : 6, 11, 16, 18 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 4 Types (6, 11, 16, 18) Screening)	550

	RPR – nticardiolipin est)	(Syphilis RPR (Rapid Plasma Reagins),		210
A09.05.007	(Fe)			190
	()	()		190
	(Unsaturated Iron Binding Capacity, UIBC)			250
	/ /	(+ /Potassium, Na+ /Sodium, I- /Chloride, Serum)		230
	(g)	(Magnesium (Mg), Serum)		
	(Ferritin)			460
-	()	(C-Reactive Protein, CRP)		310
	()	(Transferrin)		440
25-OH	D	(25-OH Vitamin D Total, 25(OH)D, 25-Hydroxycalciferol)		1920
A09.05.083		HbA1 (HbA1 , Glycated Hemoglobin, GHB)		460
A09.05.023				130
A09.05.214		(Homocysteine)		1290
A09.05.010		(Protein Total)		150
A09.05.011		(Albumin)		210
	()	(Prostate-Specific Antigen		440
Total, PSA Total)				
-125 (125)	(Carbohydrate Antigen -125, Cancer Antigen -125)		580
SCC ((Squamous Cell Carcinoma Antigen, SCCA,		2260
SCCAg)				
A09.05.020				150
A09.05.018		(Uric cid)		150
A09.05.017				150
A09.05.025		() (Triglycerides)		190
A09.05.004				200
A09.05.028		()		150
	-	(Low-Density Lipoprotein Cholesterol, LDL Cholesterol)		190
A09.05.026		() (Cholesterol Total)		
A09.05.021				150
A09.05.039		(, L- , +) (Lactate		150
Dehydrogenase, LDH)				
A09.05.046		() (Alkaline Phosphatase, ALP		150
A09.05.063		(4)		350
A09.05.065		()		330

	(- ,) (Anti-thyroid Peroxidase Antibodies, Antimicrosomal Antibodies, TPO Antibodies, TPOAb, Anti-TPO)	390
	(3) (Free Triiodothyronine, FT3)	350
	(2) (Estradiol, E2)	350
	(Insulin)	490
	HOMA-IR (Insulin Resistance: Fasting Glucose/Insulin, Homeostasis Model Assessment of Insulin Resistance, HOMA-IR)	670
	(Prolactin)	350
	() (Follicle Stimulating Hormone, FSH)	350
	() (Luteinizing Hormone, LH)	350
	(,) (Growth Hormone, GH)	470
A09.05.065	()	330
	(Testosterone)	350
	- (-S04, Dehydroepiandrosterone sulfate, DHEA-S)	350
	(2) (Estradiol, E2)	350
	(Calcitonin)	860
B03.016.006	(Complete Urinalysis, Microscopic Examination)	230
B03.016.014	(Nechiporenko's Urine Test)	230
A09.28.027	(- ,) (Amylase, 24-Hour or Timed Urine)	230
	(Lipid Profile: Extended)	2640
B03.016.005	(Lipid Profile: Screening)	700
A12.05.005	(Blood Group, 0)	230
A12.05.006	- (-) (Rh-factor, Rh)	230
		680
	(Zn) (Zinc (Zn), Serum)	250
A12.05.027	(,), (Prothrombin, Prothrombin Time, PT, International Normalized Ratio, INR)	230
A09.05.051.001	D- (D-Dimer)	1030
	(ThinPrep®)	1200

12	JAK2	(,) (Analysis of JAK2 Exon 12 mutations (PCR qualitative))	4390
	MPL	(,) (Analysis of MPL gene mutations, deletions, (PCR qualitative))	4390
	CALR	(,) (Analysis of CALR gene mutations, deletions, insertions, PCR, qualitative)	4390
(Urine Culture. Bacteria Identification and Antibiotic Susceptibility Testing)			800
A12.20.001			450
Total, IgE Total)	E (IgE,) (Immunoglobulin	390
B01.058.001	(,)	-	1200
B01.058.002	(,)	-	1100
B01.001.001	(,)	-	1500
B01.001.002	(,)	-	1200
B01.001.002	()	-	800
A11.20.011			1500
A11.20.014			1500
A11.20.008			5400
A11.20.008.001			2900
A11.20.005			300
A11.20.002			300
A11.20.002			450
A11.20.003			800
A03.20.001			1000
A11.20.015			500
A16.20.036			2100
A08.20.004		()	1400
A11.20.015			500
A14.20.002		()	900
A16.20.036.001			7500
A16.20.061.001			40500
A16.20.061.001			35000
A16.20.038			39000
A16.20.016			39900
A16.20.017.001			34900

A16.20.004.001			30900
A16.20.003.001	-		36900
A16.20.041.001			29900
A16.20.001.001 ()			34900
A16.20.001.001 ()			37900
A16.20.003.001			30900
A16.20.010.001		()	73900
A16.20.010.001	2	()	75900
A16.20.010.003		()	74900
A16.20.010.003		1 ()	84900
A16.20.010.003		2 ()	58900
A16.20.010		()	83900
A16.20.011.001		()	94900
A16.20.011.001		()	76900
A16.20.011.002		()	87900
A16.20.011.002	2	()	92900
A16.20.063			35900
A16.20.033			77900
A16.20.012			1100
A11.20.003			19000
A03.20.003			60750
A16.20.042.003 ()			-
A16.20.035.001		()	58900
A16.20.035.001		()	39900
A16.20.035.001		()	61900
A16.20.028.002			20900
A16.20.028.003			20900
A16.20.083			38900
A16.20.023			31900
A16.20.065			21900
A16.20.063.018			21900
A03.20.003			17000
A03.20.003.001	1		26900
A03.20.003.001	2		33900
A03.20.003.001	3		39900
A16.20.066			4100
A11.20.018)		()	2900
A16.20.059			950
A16.20.059.001			3900

A16.20.036		5900
A16.20.091.001		2800
A11.20.008.001		2000
A11.20.008.002		2700
A16.20.006		42000
A16.20.007		28900
A16.20.098	(1)	27770
A16.20.098 +)	(2)	41000
A16.20.083		46000
A16.20.029		27770
A16.20.024		63000
A16.20.028.005	(1)	49000
A16.20.028.005	(2)	60000
A16.20.019 +		120000
A11.01.013		10200
A11.01.013		19000
A11.01.013		26900
(7 +), (Identification of Sexually Transmitted Infections (STI) Pathogens, Scrape of Urogenital Epithelial Cells)*		1350
(4 +): Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, (Identification of Sexually Transmitted Infections (STI) Pathogens, Chlamydia trachomatis DNA, Neisseria gonorrhoeae DNA, Trichomonas vaginalis DNA, Mycoplasma genitalium DNA, Human DNA)		930
+ ,o 16 18 (HPV DNA, Scrape of Urogenital Epithelial Cells, 2 Types (16, 18))		350
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68))	14 :	350
() 14 : 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)		900
(Neisseria gonorrhoeae, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Neisseria gonorrhoeae,), (GC, Neisseria gonorrhoeae Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		900
(Bacterial Vaginosis, BV)		1540
(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Urogenital Epithelial Cells)*		250
A08.20.017.002 (; ThinPrep®)		1200
A08.20.004		600
(; ; -)*		2200
(INBIOFLOR-Comprehensive Study of Microflora Composition of Urogenital Tract (UGT))		2780
(), (Antiphospholipid Syndrome, APS)		3570

(Genitourinary Tract Culture, Bacteria Identification and Antibiotic Susceptibility Testing)*		1160
(Vaginal Biocenosis: Bacteriophage and Antimycotic Susceptibility Testing (Gram Stain, Bacterioscopic Examination of Smear))*		1500
(The Bethesda System ? TBS) (Cytological Examination of Cervical Epithelium with Description on The Bethesda System, TBS)		570
MICROBIOCENOSIS (PCR Panel Femoflor 16)	16. (UROGENITAL TRACT	2100
		450
(Cytological Examination: Cervix, Pap-test)		1000
(Candidiasis, Screening and Typing)		920
MICROBIOCENOSIS, Screening (PCR Panel Femoflor Screen))	(UROGENITAL TRACT	1850
MICROBIOCENOSIS (PCR Panel Femoflor 8)	8. (UROGENITAL TRACT	1480
B01.053.001	(,) -	1200
B01.053.002	(,) -	1100
A16.28.040	(1)	2100
		10000
A16.28.058		1000
A16.28.052.001		2400
A16.28.072.001		2400
A11.28.008		1600
A11.28.006.001		500
A21.21.001		550
A12.21.003		650
A15.21.001	()	1000
A03.28.002		3500
A03.28.003	()	6000
A03.28.001		5000
A16.28.077	-	5000
A11.28.012		1000
A16.21.015		2300
A16.28.013.001		1000
A06.28.007		5000
A06.28.011		5000
()		10000
B01.015.001	(,) -	1200
B01.015.002	(,) -	1100
B01.008.003	()	1200

B01.008.004	()		1100
A11.02.002	(1)		260
A11.02.002	(1)		290
A11.01.003	.1		2999
A11.01.003	.2		4999
A11.01.003 PRP-	1 (1)		5000
A11.01.003	mesoline () 2,5 .		2500
A11.01.003	mesoline () 2,5 .		2500
A16.01.024	(PRX-t33)		3750
A16.01.024			2000
A16.01.024			2500
A14.01.008			3000
			2000
B01.028.001	(,) -		1200
B01.028.002	(,) -		1100
B01.028.002	() -		800
A11.01.014			200
A12.25.001			1000
A11.07.004	()		1500
A11.08.001	()		5000
	()		3000
A11.25.006	()		3000
			350
			200
A11.08.019			600
A16.01.012	(, ,) -		3000
A16.08.054			1500
A16.08.010.001	() (RadioSURG)		10000
A11.08.007			1000
			100
A03.25.003			300
A22.30.033			2200
A11.08.022	(-) - (1)		2500
A11.08.022	(-) - (2)		3500
A21.25.002			250
A11.07.022			300
	(,)		800
A16.01.004			400

A15.01.002					1000
					800
A16.08.006.001	(1)				2000
					2000
A12.25.006					300
					700
A11.08.021.001					700
A16.08.016					600
A16.25.007	(1)				500
A11.08.004					1300
A16.08.023	(1)				1800
A16.08.023	(2)				3000
					250
					350
A11.25.003.001					600
A16.01.017.001		-	1	.(1	3300
)					
A16.01.017.001		-	1	3 .(1	3500
)					
A16.25.008					1500
A16.08.011					1200
					500
	()				900
	()				1400
	()				1200
B01.003.004.004					300
					300
B01.003.004.005	(I)				500
B01.003.004.005	(II)				700
B01.003.004.005	(III)				900
	()				200
	()				200
	()				200
A11.08.020					200
	()				6000
A03.25.001					400
A16.08.012					800
					700
					300
A16.01.017.001		-	1	.(1	3800
)					
A16.01.017.001		-	1	3 .(1	4000
)					
					4000
A16.08.009.001		-1	:	1	10000
A16.08.009.001		-1	:	2	20000
A16.08.009.001		-1	:	3	30000
A16.08.010.001	()		:	1	10000

A16.08.010.001	(): 2	15000
A16.08.010.001	(): 3	20000
A16.25.020			13000
A16.25.011	()	1500
A16.25.011	(2000
B01.003.004.001	()	1000
	:	1	12000
	:	2	15000
	:	3	20000
			700
			1000
A16.08.013	(): 1	18000
A16.08.013	(): 2	24000
A16.08.013	(): 3	29000
A16.08.001	() 1	31000
			1000
A16.08.014		1	10000
A15.03.003			1500
	-		7000
A16.08.012			3500
A16.08.017.001		1	30000
A16.08.017.001		2	37000
A16.08.017.001		3	42000
A16.08.035			35000
A16.08.002		1	25000
A16.08.002		2	34500
A16.08.001		3	39000
A16.08.001	() 2	34000
A16.08.001	() 3	39000
			5000
A16.08.064		1	15000
A16.08.064		2	20000
A16.08.064		3	25000
A16.08.014		2	15000
A16.08.014		3	20000
			710
			2200
A04.12.014			900
	()	1300
A04.12.003.001	()	900
A04.12.002.002			1100

A04.12.002.001		2000
A04.12.002		1800
A04.12.002.003		1000
A04.12.001		1000
A04.12.001.001		1100
A04.12.001.002		600
()		1500
A04.22.001		500
		700
		800
A04.16.001	(, , , ,)	1100
	(, , , ,)	1800
A04.14.001		700
A04.14.002		500
A04.14.002.001		650
A04.06.001		500
A04.15.001		500
A04.18.001		500
A04.28.002.001		800
A04.22.002		400
A04.28.001		700
A04.28.002.001		600
A04.28.002.005		600
A04.28.002.003		500
A04.28.003		700
A04.10.002	(+)	1650
A04.01.001	()	750
A04.09.001		600
A04.06.003		600
A04.06.002		800
A04.06.002		800
A04.06.002		600
A04.06.002	/	600
A04.06.002		600
A04.06.002		600
A04.06.002	, / , , , ,	1900
A04.21.001		700

A04.20.001	()		850
A04.20.002	()		850
A04.20.002.001	()		950
A04.20.002	()		700
A04.23.001	()		900
(+)			
A04.23.001	()	()	700
A04.03.001	1		700
A04.07.002			600
A04.08.001	(4-5)		500
A04.04.001.001	(1)		600
A04.03.001			600
A04.04.001	(- / -)		450
B01.059.001	(,) -		1200
B01.059.002	(,) -		1100
A03.08.004.002			6900
A03.16.001	()		2300
A11.16.002	- ()		900
	IgA Helicobacter pylori)		850
A26.19.098	Helicobacter pylori ()		870
A11.16.002	/		1040
	Helicobacter pylori IgG (-)		3220
A11.16.002	()		400
A03.16.001.005	()		2900
			2000
A11.16.001	()		400
A11.16.003	()		400
A03.16.001.001			4900
A03.16.001.004			2400
A11.16.010			1100
A16.12.020.002			4900
A16.16.041.001			6500
A16.16.041.003			5000
A16.16.048			5000
A03.18.001.001			2600
A03.19.002			1800
A11.18.001	()		400
A11.19.001	()		400

A11.19.002)	(400
A16.18.019.001	(1)	6900
A16.18.019.001	(1 2-)	8100
A16.18.019.001	(2-)	10900
A03.18.002		11900
A03.19.004		3100

A03.09.001		2900
A03.08.001.001	()	2600
A11.07.016.001)	(400
A11.08.003.001 ()		400
A11.08.008.001 ()		400
A11.08.012.001 ()		400
A03.09.002		2900
A03.09.003		3300
A03.16.002		500
A03.30.006.001		2900
A11.09.008		400

()		1200
()		1100

B01.027.001	(,) -	1200
B01.027.002	(,) -	1100

(60)		2100
-------	--	------

Check-Up	45	11499
Check-Up	40	12799
Check-Up	45	15599
Check-Up	40	16999
Check-Up (-)"	" 40	7100
Check-Up (-)"	" 40	8800
")	" (; ;	2990
)	(+	1999
")	" (+	1600
+)	+ + +	7500

B01.004.001	(,) -		1200
B01.004.002	(,) -		1100

A11.12.003.001 ()			400
A11.12.003	()		250
A11.01.002			170
A11.02.002			200
A11.16.010			1100

A11.12.003.001 () 2 .			200
A11.12.003.001 () 8			100
A11.12.003.001 () 5			100
A11.12.003.001 () 30 /1 (1)			50
A11.12.003.001 () 5 / 100 (1)			450
A11.02.002 5 / (1)			50
A11.02.002 50 / (1)			50
A11.12.003.001 () 10			230
A11.12.003.001 () 5			300
A11.02.002		2 .	200

()			1200
()			1100

B01.008.001	(,) -		1200
B01.008.002	(,) -		1100

B01.023.003 3-)	-	(1200
B01.058.006 3-)	-	(1200
B01.047.009 3-)	-	(1200

B01.003.001	() -	-	1200
B01.003.002	() -	-	950

B01.003.004.009	()		3200
B01.003.004.009			4200
B01.003.004.009	()		5300

B01.003.004.009		30		5500
B01.003.004.009		1		10000
B01.003.004.012			30	6500
B01.003.004.012			1	12000
B01.003.004.009		1,5		15000
B01.003.004.007		1		9900
B01.003.004.007		2-		14000
B01.003.004.008	-	1		11900
B01.003.004.008	-	2-		16000
B01.003.004.007		30		5500
B01.003.004.010			(1)	12760
B01.003.004.010			(1,5)	17760

				5000
				5000
B01.003.003	-	-		5000
				3000

				1200
				1100

				6500
				3100
				1500
				2100
				15000
				2100
				5900
				15000
				1800
				1100
				600
				600
				700
				6100
				10000
				8600
				11600
				15100
				7000

				10100
--	--	--	--	-------

(,1)2	15100
(/)1	11900
(/)2	15900
)1 (6300
)2 (9300
()1	19000
()2	23000
()3	29000
()1	27000
()2	31900
()3	45100
1	20100
2	24100
3	37100

"A" "M", "A1" "B1"	1300
"A" "M", "A1" "B1" ()	1700
"B" "BE", "B1" ()	1300
"B" "BE", "B1" () (-)	1700

B01.050.001 (,) - -	1200
B01.050.002 (,) - -	1100

A11.04.003	1100
A11.04.004	1200
A15.02.001	500
A15.03.001	500
A15.03.003	700
A15.03.003.002	600
A15.03.007	600
A15.03.009	700
A15.03.010 ()	500
A15.03.010.001	600
A15.04.001 ()	700
A16.02.007 ()	29900
A16.02.008 ()	29900
A16.02.009	26000

MVK, . (Mevalonic Aciduria, Gene MVK, Mut.)	38910
. (Mandibuloacral Dysplasia, Exons 8, 9 Gene LMNA, Mut.)	6510
I, II, III, IV (SMN2) (Spinal Muscular Atrophy, SMA, Type I, II, III, IV (copy Number Variation SMN2))	15070
CHRNA, . (Escobar Syndrome, Gene CHRNA, Mut.)	31140
BCL2, . (Silver Syndrome, Gene BCL2, Mut.)	27250
Hemophagocytic Lymphohistiocytosis, Gene STX11, Mut.)	12970
-1- , SERPINA1, . .	1850
I, II, III, IV. SMN1, . ((Spinal Muscular Atrophy, SMA, Type I, II, III, IV, Gene SMN1, Mut. (Only Presence One Gene Copy))	31140
CINCA, NLRP3 . (Chronic Infantile Neurologic Cutaneous Articular, Gene NLRP3, Mut.)	46680
TBX3, . (Pallister W Syndrome, Gene TBX3, Mut.)	27250
(Oculopharyngeal Muscular Dystrophy, OPMD, Gene RABPN1, Freq. Mut.)	4680
(Gerstmann-Straussler Disease, Gene PRNP, Mut.)	13560
(Bloch-Sulzberger Syndrome, Familial Incontinentia Pigmenti, Gene IKBKG, Freq. Mut.)	4680
GJB2	10240
NS3, NS5A NS5B	11670
(3)	19480
RAB27A, . (Griscelli Syndrome, Gene RAB27A, Mut.)	27250
Angioedema Type I, Gene C1NH, Mut.)	27250
((- -) I. 22, . (Charcot-Marie-Tooth Disease Type 1B, Gene 22, Mut.)	15930
HRAS, . (Costello Syndrome, Gene HRAS, Mut.)	6510
RMRP, .	6510
(Metaphyseal Chondrodysplasia, McKusick Type, Gene RMRP, Mut.)	37750
MEFV, . (Familial Mediterranean Fever, FMF, Gene MEFV, Mut.)	6510
SBDS1, . . .	3000
(Shwachman-Diamond Syndrome, Gene SBDS1, Freq. Mut.)	27250
HLA-A29	27250
ACVR1, « » . . (Fibrodysplasia Ossificans Progressiva, FOP, Gene ACVR1, without Hot-Point Mut.)	27250
EDNRB, . (Waardenburg-Shah Syndrome, Gene EDNRB, Mut.)	85530
ERCC6, . (Cockayne Syndrome, Gene ERCC6, Mut.)	23370
SLC26A2, . (Diastrophic Dysplasia, Gene SLC26A2, Mut.)	12970
B1. ROR2, . (Brachydactyly Type B1, Gene ROR2, Mut.)	69990
(). GLI3, . (Greig Syndrome, Gene GLI3, Mut.)	8100
((- -) I. EGR2, . (Charcot-Marie-Tooth Disease Type 1B, Gene EGR2, Mut.)	15600
Gene FGFR2, Mut.)	9090
7 9 FGFR2, . (Crouzon Syndrome, Exons 7, 9	35020
- a - a (). ENG, . (Rendu-Osler-Weber Disease, Gene ENG, Mut.)	10240
Exudative Vitreoretinopathy, FEVR, Gene NDP, Mut.)	38910
LMNA, . (Familial Partial Lipodystrophy 2, Gene LMNA, Mut.)	27250
(). LMX1B, .	
(Nail-Patella Syndrome, NPS, Onychoosteodysplasia, Gene LMX1B, Mut.)	

Mut)	SGCE, . (Myoclonic Dystonia, Gene SGCE,	46680
ATP7B, Freq. Mut.)	ATP7B, . . (Wilson Disease, Gene	9350
NGF, Mut.)	, NGF . (Hereditary Sensory and Autonomic olyneuropathy, Gene	15600
syndrome, Gene ALMS1, Hot-Point Mut.)	« » ALMS1, « . » . . (Alstrom	12970
TCOF1, . (Treacher-Collins Syndrome, Franceschetti-Klein Syndrome, Mandibulofacial Dysostosis without Limb Anomalies, Gene TCOF1, Mut.)	(.)	85530
	GJB3, . (Erythrokeratodermia, Gene GJB3, Mut.)	10240
, GLA, .		9200
« » TRPV4, « . » . . (Distal Spinal Muscular Atrophy Congenital Non-Progressive, Gene TRPV4, Hot-Point Mut.)		12970
Primary Carnitine Deficiency, SPCD, Carnitine Deficiency Systemic Primary, CDSP, Gene SLC22A5, Mut.)	SLC22A5, . (Systemic	38910
Mut.)	FXN, . . (Friedrich Ataxia, Gene FXN, Freq.	8200
EMG1, . (Bowen Conradi Syndrome, BCS, Gene EMG1, Mut.)	(,)	15600
(Leber Hereditary Optic Neuropathy, LHON, Mitochondrial DNA, 3 Freq. Mut.)	, 3 . .	4680
Syndrome, Gene BCS1L, Mut.)	() BCS1L, . (Bjomstad	15930
TWIST1, Mut.)	TWIST1, . (Saethre-Chotzen Syndrome, Gene	13560
GDAP, . (Charcot-Marie-Tooth Disease Type 2A1, Gene GDAP, Mut.)	(- -) II.	23370
COMP, Freq. Mut.)	COMP, . . (Pseudoachondroplasia, Gene	6200
Gene NPHS1, Mut.)	NPHS1, . (Nephrotic Syndrome Type 1, NPHS1,	69990
Mut.)	FGFR3, . . (Achondroplasia, Gene FGFR3, Freq.	10960
Syndrome, FCAS, Gene NLRP3, Mut.)	NLRP3 . (Familial Cold Autoinflammatory	46680
O, . (Charcot-Marie-Tooth Disease Type 1B, Gene O, Mut.)	(- -) I.	15600
DLL3, Mut.)	DLL3, . (Spondylocostal Dysostosis, Gene	27250
NPHP1, . (Nephronophthisis 1, NPHP1, Gene NPHP1, Mut.)		15460
Muscular Dystrophy, Gene FHL1, Mut.)	FHL1, . (Emery-Dreifuss	31140
Dihydrate, CPPD, Gene ANKH, Mut.)	ANKH, . (Chondrocalcinosis, Calcium Pyrophosphate	46680
MULIBRAY. Mut.)	TRIM37, . (Muscle-Liver-Brain-Eye, Gene TRIM37,	9090
(Leber Hereditary Optic Neuropathy, LHON, Mitochondrial DNA, 12 Freq. Mut.)	, 12 . .	12970
Ataxia, Gene ATXN7 Freq. Mut.)	ATXN7, . . (Spinocerebellar	4680
IGHMBP2, . (Distal Spinal Muscular Atrophy 1, DSMA1, Gene IGHMBP2, Mut.)		58330
RP2, Mut.)	RP2, . (Retinitis Pigmentosa, Gene	19480
Syndrome, Type VI, Gene PLOD, Freq. Mut.)	VI. PLOD, . . (Ehlers-Danlos	9350
(Aarskog-Scott Syndrome, Faciodigitogenital Syndrome, Faciogenital Dysplasia, Gene FGD1, Mut.)	() FGD1, .	57020
Spinal and Bulbar Muscular Atrophy, Gene AR, Freq. Mut.)	AR, . . (Kennedy	4680
	PCSK9	10620
(X)		5790

	/	FMR1, . . .	3100
Mut.)		GLI3, . (Pallister-Hall Syndrome, Gene GLI3,	69990
ABS, Exon 9 Gene FGFR2, Mut.)	9	FGFR2, . (Antley-Bixler Syndrome,	6510
(Pfeiffer Syndrome, Exons 7, 9 Gene FGFR2, Exon 7A Gene FGFR1, Mut.)	7, 9	FGFR2 7A FGFR1, .	12970
	/		10730
(Familial Hemophagocytic Lymphohistiocytosis, Gene UNC13D, Freq. Mut.)		UNC13D, . . .	4680
(Autoimmune Lymphoproliferative Syndrome, ALPS, Gene TNFRSF6, Mut.)		TNFRSF6, .	31140
(Familial Meddular Thyroid Cancer, Exons 5, 8 Gene RET, Mut.)	5, 8	RET, .	9090
Syndrome, Gene SBDS, Mut.)		SBDS, . (Shwachman-Diamond	19480
Mut.)		KCNJ2, . (Andersen-Tawil Syndrome, Gene KCNJ2,	15930
	(1- .).	10960
ABCA4, . . . (Stargardt Disease 1, STGD1, Fundus Flavimaculatus Included, Gene ABCA4, Freq. Mut.)		CHM, . (Choroideremia, CHM, Gene CHM, Mut.)	58330
			6900
WWS, Gene FKRP, Mut.)	(FKRP, . (Walker-Warburg Syndrome,	13560
Syndrome with Acanthosis Nigrigan, CAN, Exon 10 Gene FGFR3, Mut.)	10	FGFR3, . (Crouzon	6510
Agammaglobulinemia, XLA, Gene BTK, Mut.)		BTK, . (X-Linked	69990
	D-	(85530
PHEX, . (Hypophosphatemic Vitamin D-Resistant Rickets, Gene PHEX, Mut.)		GRN, . (Aphasia Primary	23370
Progressive, Gene GRN, Mut.)		XK, . (McLeod Syndrome, Gene XK, Mut.)	15600
(Testicular Feminization Syndrome, Gene AR, Mut.)	(AR, .	38910
Ectodermal Dysplasia, Gene EDA, Mut.)		EDA, . (Anhidrotic	31140
UPK3A, Mut.)		UPK3A, . (Renal Hypodysplasia, Aplasia 1, Gene	23370
Mut.)		PAH, . . (Phenylketonuria, PKU, Gene PAH, Freq.	15460
« . . » . . . (Optic Atrophy With Or Without Deafness, Ophthalmoplegia, Myopathy, Ataxia And Neuropathy, Gene OPA1, Hot-Point Mut)		OPA1,	9090
Dominant, SCN1, Gene ELA2, Mut.)		ELA2, . (Neutropenia Severe Congenital 1 Autosomal	19480
		APOB100	4380
(Congenital Insensitivity To Pain With Anhidrosis, CIPA, Gene NTRK1, Mut.)		NTRK1, .	46680
Epiphysial Dysplasia, MED, Gene COMP, Freq. Mut.)		COMP, . . (Multiple	6200
PHOX2B, . . . (Congenital Central Hypoventilation Syndrome, CCHS, Gene PHOX2B, Freq. Mut.)	(4680
(Genes CFTR, GJB2, PAH, SMN))	(CFTR, GJB2, PAH, SMN) (Main Hereditary Diseases	19220
Gene DMPK, Freq. Mut.)		DMPK, . . (Myotonic Dystrophy 1,	4680
	(- -) I.	9090
ongenital Ichthyosis, ARCI 1, All Known Mutations, Gene TGM1, Mut.)		TGM1, . (Autosomal Recessive	38910
Motor Neuropathy, DHMN, Gene BSCL2, Mut.)	V.	BSCL2, . (Distal Hereditary	27250
Mut.)		ZEB2, . (Mowat-Wilson Syndrome, Gene ZEB2,	58330

(Phosphoribosylpyrophosphate Synthetase Superactivity, PRS Superactivity, Gene PRPS1, Mut.)	PRPS1, .	27250
(Albinism oculocutaneous, Hermansky-Pudlak type, Gene HPS1, Freq. Mut.)	HPS1, . .	9090
		21400
(Klippel-Feil Syndrome, Gene GDF6, Mut.)	GDF6, .	13560
(Cranio metaphyseal Dysplasia, Gene ANKH, Hot-Point Mut.)	ANKH, « . » .	9090
(Nonbullous Congenital Ichthyosiform Erythroderma, NBCIE, Gene TGM1, Mut.)	TGM1, .	38910
(Creutzfeldt-Jakob Disease, Gene PRNP, Mut.)	PRNP, .	13560
(Microphthalmia with Cataract, Gene CRYBA4, Mut.)	CRYBA4, .	23370
		6900
(TNF-Receptor-Associated Periodic Syndrome, TRAPS, Gene TNFRSF1A, Mut.)	TNFRSF1A, .	23370
(Cerebelloparenchymal Disorder IV, CPD IV, Classic Joubert Syndrome, Joubert Syndrome type A, Joubert-Boltshauser Syndrome, Pure Joubert Syndrome, Gene NPHP1, Mut.)	NPHP1 (Joubert Syndrome,	15460
(Methemoglobinemia, Gene CYB5R3, Freq. Mut.)	CYB5R3 . .	4680
(Chorea Huntington, Gene IT15, Freq. Mut.)	IT15, . .	4680
(Simpson-Golabi-Behmel Syndrome, Type 1, SGBS1, Gene GPC3, Mut.)	GPC3, .	31140
(3-Methylglutaconic Aciduria Type III, Gene OPA3, Mut.)	OPA3, .	10240
(X-Linked Lymphoproliferative Syndrome, XLP, Gene XIAP, Mut.)	(), XIAP	31140
(Familial Mediterranean Fever, FMF, Gene MEFV, Freq. Mut.)	MEFV, . .	9070
(Disorders Sex Determination, Gene SRY, Mut.)	SRY, .	6510
(Hidrotic Ectodermal Dysplasia, Gene GJB6, Mut.)	GJB6, .	10240
(X-Linked Nystagmus congenital 1, NYS1 X-Linked, Gene FRMD7, Mut.)	FRMD7, .	46680
(Parietal Foramina, PFM, Gene ALX4, Mut.)	ALX4, .	15600
(Wiskott-Aldrich Syndrome, WAS, Gene WAS, Mut.)	WAS, .	27250
(Emery-Dreifuss Muscular Dystrophy, X-Linked Gene Emerine, Mut.)		13560
(Acrodermatitis Enteropathica, Gene SLC39A4, Mut.)	SLC39A4, .	31140
(Hereditary Neuropathy with Liability to Pressure Palsies, HNPP, Gene 22, Mut.)	22, .	15930
(Osteopetrosis Autosomal Recessive 1, OPTB1, Gene TCIRG1, Freq. Mut.)	(), TCIRG1,	4680
(Hypokalemic Periodic Paralysis Type 1, Exons 12, 18, 19 Gene SCN4A, Mut.)	12, 18 19 SCN4A, .	12970
(Ichthyosis Vulgaris, Gene FLG, Freq. Mut.)	FLG, .	9090
	LDLR	11670
(Hyper-IgD Syndrome, Gene CD40LG, Mut.)	CD40LG, .	38910
(Albinism Oculocutaneous Type IA, Gene TYR, Mut.)	TYR, .	19480
(Muscular Dystrophy-Dystroglycanopathy, Gene FKR1, Freq. Mut.)	FKR1, . .	7160
(Stargardt Disease 1, STGD1, Fundus Flavimaculatus Included, Gene ABCA4, Freq. Mut.)	ABCA4, . .	10960
(Spondyloepiphyseal Dysplasia Tarda, SEDT, Gene TRAPPC2, Mut.)	(), TRAPPC2, .	15600

Pneumothorax, PSP, Gene FLCN, Mut.)	FLCN, . (Primary Spontaneous	46680
, NBN . . (Nijmegen Breakage Syndrome, NBS, Gene NBN, Freq. Mut.)		4680
PAX3, Mut.)	PAX3, . (Waardenburg Syndrome, WS, Gene	31140
Dystrophy Limb-Girdle Type 2A, Gene FKRP, Mut.)	FKRP, . (Muscular	13560
	CTSK, . (Pyknodysostosis, PKND, Gene CTSK, Mut.)	23370
	PAH, . (Phenylketonuria, PKU, Gene PAH, Mut.)	46680
Syndrome, Gene DHCR7, Mut.)	DHCR7, . (Smith-Lemli-Opitz	35020
	CFTR, . . (Cystic Fibrosis, Gene CFTR, Freq. Mut.)	15460
		8000
	NOTCH3	11200
Muscular Dystrophy, X-Lyonization, Girls)	(Duchenne	7300
GDF6, Mut.)	GDF6, . (Microphthalmia Isolated 4, Gene	13560
		6900
SPM, Gene FHL1, Mut.)	FHL1, . (Scapulo-peroneal Myopathy,	31140
Hemophagocytic Lymphohistiocytosis, Gene PRF1, Mut.)	PRF1, . (Familial	19480
Gene PRNP, Mut.)	PRNP, . (Fatal Familial Insomnia, FFI,	13560
	EXT1, . (Multiple Exostoses, Gene EXT1, Mut.)	46680
Myoclonic Epilepsy 1A Unverricht and Lundborg, Gene CSTB, Freq. Mut.)	CSTB, . . (Progressive	4680
ACVR1, « » . . (Fibrodysplasia Ossificans Progressiva, FOP, Gene ACVR1, Hot-Point Mut.)	« »	15600
	2, JPH3, . .	3100
(X-Linked Severe Combined Immunodeficiency, Gene IL2RG, Mut.)	IL2RG, .	15600
	NLRP3 . (Muckle-Wells Syndrome, MWS, Gene NLRP3, Mut.)	46690
Elasticum, Gene ABCC6, Freq. Mut.)	ABCC6, . . (Pseudoxanthoma	6510
	, CYB5R3 . (Methemoglobinemia, Gene CYB5R3, Mut.)	31140
Hypertension 1, PPH1, Gene BMPR2, Mut.)	BMPR2, . (Primary Pulmonary	58330
	FXN, . (Friedrich Ataxia, Gene FXN, Mut.)	19480
	NDP, . (Norrie Disease, Gene NDP, Mut.)	10240
(Nonbullous Congenital Ichthyosiform Erythroderma, NBCIE, Gene LOX12B, Mut.)	(). LOX12B, .	38910
Cardiomyopathy, Gene TNNT2, Mut.)	TNNT2, . (Familial Hypertrophic	46680
(Primary Open Angle Glaucoma 1A, POAG 1A, Gene CYP1B1, Mut.)	(). CYP1B1, .	15930
	FLT4, . (Lymphedema, Gene FLT4, Mut.)	101070
Thrombocytopenia, CAMT, Gene MPL, Mut.)	MPL, . (Congenital Amegakaryocytic	31140
Dystrophy Limb-Girdle Type 2A, Gene SGCB, Mut.)	SGCB, . (Muscular	23370
Hypodysplasia, Aplasia 1, Exons 10, 11, 13, 14, 15 Gene RET, Mut.)	10, 11, 13, 14, 15 RET, . (Renal	19480
Heteroplasia, POH, Gene GNAS, Mut.)	GNAS, . (Progressive Osseous	35020
	(), SOD1, .	6700
	1, TOR1A (DYT1), . .	3100
Syndrome, PPS, Gene IRF6, Mut.)	IRF6, . (Popliteal Pterygium	35020

PTEN, Mut.)	PTEN, . (Lhermitte-Duclos Syndrome, Gene	35020
Dystrophy-Dystroglycanopathy, Gene FKRP, Mut.)	FKRP, . (Muscular	13560
Syndrome, Gene PTEN, Mut.)	PTEN, . (Bannayan-Ruvalcaba-Riley	35020
VHL, . (Autosomal Recessive Erythrocytosis, Gene VHL, Mut.)		13560
disease type 1A (CMT1A))	, PMP22, (Charcot-Marie-Tooth	15070
Gene ANKH, Mut.)	ANKH, . (Craniometaphyseal Dysplasia,	46680
Disease, CGD, Gene CYBB, Mut.)	CYBB, . (Chronic Granulomatous	46680
Syndrome, Gene LMNA, Mut.)	LMNA, . (Hutchinson-Gilford Progeria	38910
(Crigler-Najjer Syndrome, Gene UGT1, Mut.)	UGT1, .	19480
	MECP2, . (Retts Syndrome, Gene MECP2, Mut.)	19480
	HLA B51	3000
Analysis Gene SRY, Mut.)	SRY, . (Disorders Sex Determination,	4680
Dystrophy Limb-Girdle Type 2A, Gene SGCA, Mut.)	SGCA, . (Muscular	23370
	NEFL, . (Charcot-Marie-Tooth Disease Type 2A1, Gene NEFL, Mut.)	23370
TNFRSF6, « » . (Autoimmune Lymphoproliferative Syndrome, ALPS, Gene TNFRSF6, Hot-Point Mut.)		6510
-IgD Syndrome, Gene MVK, Hot-Point Mut.)	MVK, « » . (Hyper-IgD	9090
Fukuyama-Type, Gene FKTN, Mut.)	FKTN, . (Muscular Dystrophy	46680
ESC () .	NR2E3, . (Enhanced S- one	23370
Syndrome, Goldmann-Favre Syndrome, Gene NR2E3, Mut.)		
Mut.)	IRF6, . (Van der Woude Syndrome, Gene IRF6,	35020
Mut.)	RS1, . (Retinoschisis 1 X-Linked Juvenile, RS1, Gene RS1,	23370
Hemophagocytic Lymphohistiocytosis, Gene UNC13D, Mut.)	UNC13D, . (Familial	69990
(Osteopetrosis Autosomal Recessive 1, OPTB1, Gene TCIRG1, Mut.)	TCIRG1, .	46680
1A Unverricht and Lundborg, Gene CSTB, Mut.)	CSTB, . (Progressive Myoclonic Epilepsy	12970
Mut.)	SH2D1A, . (X-Linked Lymphoproliferative Syndrome, XLP, Gene SH2D1A,	15600
Dystrophy, All Known Mutations, Gene BEST1, Mut.)	BEST1, . (Best Vitelliform Macular	38910
	TWIST1, . (Craniosynostosis Type 2, Gene TWIST1, Mut.)	13560
	MSX2, . (Craniosynostosis Type 2, Gene MSX2, Mut.)	10240
PRNP, . (Spongiform Encephalopathy with Neuropsychiatric Features, Gene PRNP, Mut.)		13560
Mut.)	KRT2, . (Ichthyosis Bullosa Of Siemens, Gene KRT2,	27250
RAB23, . (Carpenter Syndrome, Gene RAB23, Mut.)		27250
(Jackson-Weiss Syndrome, JWS, Exon 9 Gene FGFR2, Exon 7A Gene FGFR1, Mut.)	9 FGFR2 7A FGFR1, .	9090
Gene ABCC6, Mut.)	ABCC6, . (Pseudoxanthoma Elasticum,	108840
	4, SPAST (SPG4), . .	6300
VHL, . (Von Hippel-Lindau Syndrome, VHL, Von Hippel-Lindau Hereditary Cancer Syndrome, Gene VHL, Mut.)		13560

HLA-Cw6	3000
-	5090
(Syndrome, AS, Gene FGFR2, Freq. Mut.)	9350
(LDLR, APOB, PCSK9)	8380
Epiphyseal Dysplasia, MED, Gene SLC26A2, Mut.)	23370
PRPS1, (Art's Syndrome, Gene PRPS1, Mut.)	27250
((Nonbullous Congenital Ichthyosiform Erythroderma, NBCIE, Gene ALOXE3, Mut.)	58330
PAX3, (Craniofacial-Deafness-Hand Syndrome, CDHS, Gene PAX3, Mut.)	31140
Muscular Dystrophy, Gene LMNA, Mut.)	38910
(VHL, (Autosomal Recessive Erythrocytosis, Gene VHL, Freq. Mut.)	4680
(Keratitis-Ichthyosis-Deafness Syndrome, KID Syndrome, Gene GJB2, Mut.)	9090
« » (Familial Partial Lipodystrophy 2, FPLD 2, Gene LMNA, Hot-Point Mut.)	12970
TAZ, (Barth Syndrome, Gene TAZ, Mut.)	23370
(Cerebrooculofacioskeletal Syndrome, COFS Syndrome, Gene ERCC6, Mut.)	85530
(VHL, (Von Hippel-Lindau Syndrome, VHL, Von Hippel-Lindau Hereditary Cancer Syndrome, Gene VHL, Copy Number Variation Gene VHL, Mut.)	15070
EXT2, (Multiple Exostoses, Gene EXT2, Mut.)	58330
ANO5, SGCA	10960
3A, Gene CYP1B1, Mut.)	15930
(Normokalemic Periodic Paralysis, Exon 13 Gene SCN4A, Mut.)	6510
ATP7B, PNPLA3, SERPINA1, . . .	8400
GLI3, (Polydactyly, Gene GLI3, Mut.)	69990
-IgM Mut.)	19480
CD40LG, (Hyper-IgM Syndrome, Gene CD40LG, Mut.)	19480
HPGD, (Hypertrophic Osteoarthropathy, Primary, Autosomal Recessive, 1, Gene HPGD, Mut.)	27250
Gene CLCN1, Freq. Mut.)	9350
, C9orf72, . . .	4200
And Diabetes Syndrome, Gene HNF1B, Mut.)	35020
(SH3TC2, FIG4, FGD4 GDAP1, . . . (Charcot-Marie-Tooth Disease Type 1B, Gene GDAP1, Freq. Mut.)	9350
(Gene RPS6KA3, Mut.)	85530
RPS6KA3, (Coffin-Lowry Syndrome, Mut.)	85530
SHH, (Polydactyly, Gene SHH, Mut.)	9090
, PNPLA3, . . .	2900
TAR. TAR-Syndrome, Gene RBM8A, Mut.)	23370
RBM8A, (Thrombocytopenia-Absent Radius Syndrome, Mut.)	23370
PTEN, (Cowden Syndrome 1, Gene PTEN, Mut.)	35020
, 2, CNBP (ZNF9), . . .	2800
EBP, (Chondrodysplasia Punctata, CDP, Conradi-Hunermann Syndrome, Gene EBP, Mut.)	15600
STXBP2, (Familial Hemophagocytic Lymphohistiocytosis, Gene STXBP2, Mut.)	46680
(Autosomal Recessive, Gene LPIN1, Mut.)	85530
LPIN1, (Myoglobinuria Acute Recurrent Gene ADAMTSL2, Mut.)	85530
ADAMTSL2, (Geleophysic Dysplasia 1, Mut.)	69990

(Neurodegeneration With Brain Iron Accumulation 1, Gene PANK2, Freq. Mut.)	PANK2	6510
	GJB4, (Erythrokeratoderma, Gene GJB4, Mut.)	9090
(II, De la Chapelle Dysplasia, Gene SLC26A2, Mut.)	SLC26A2, (Atelosteogenesis)	23370
DBA1, Gene RPS19, Mut.)	RPS19, (Diamond-Blackfan Anemia 1,	19480
NPHS1, Gene NPHS2, Mut.)	NPHS2, (Nephrotic Syndrome Type 1,	31140
IX, Mut.)	IX B, (Hemophilia B, Gene Factor	27250
Syndrome, TRPS, Gene TRPS1, Mut.)	TRPS1, (Trichorhinophalangeal	38910
Muscular Atrophy (SMA) with Diaphragmatic Paralysis, Gene IGHMBP2, Mut.)	IGHMBP2, (Spinal	58330
Freq. Mut.)	FGFR3, (Hypochondroplasia, Gene FGFR3,	10960
(1, 1b)	NS3, NS5A NS5B	11670
(Hyperkalemic Periodic Paralysis Type 2, Exons 13, 24 Gene SCN4A, Mut.)	13 24 SCN4A,	14270
DFNB1	GJB2	6200
MET		11210
(Hereditary Breast and/or Ovarian Cancer, HBOC (Genes BRCA1, BRCA2))	/ (BRCA1, BRCA2)	4350
POLE		7570
1 /19q		10150
		9100
Neoplasia Type 2B (Gene RET))	2B (RET) (Multiple Endocrine	4680
BRCA-	(BRCA1, BRCA2) (3900
(Hereditary Breast Cancer In Men: Cancer of Breast, Pancreatic, Prostate, Testicular Cancer (Genes BRCA1, BRCA2) (without Description))	(10, 11, 13, 14, 15 RET) (Familial	19460
Medullary Thyroid Cancer (Exons 10, 11, 13, 14, 15 Gene RET))	2A (10, 11 RET) (Multiple	9090
Endocrine Neoplasia Type 2A (Exons 10, 11 Gene RET))		10620
IDH2		21090
14	JAK2 (Quantification of wild-type and mutant allelic ratio of gene JAK2 617V/617F)	8000
BRCA-	(BRCA1, BRCA2) (Hereditary Breast	4350
Cancer In Men: Cancer of Breast, Pancreatic, Prostate, Testicular Cancer (Genes BRCA1, BRCA2))		10620
MGMT		10620
PIK3CA		10620
228 250 TERT		7570
(Genes BRCA1, BRCA2) (without Description))	/ (BRCA1, BRCA2) (3900
IDH1		10620
A09.05.039 Dehydrogenase, LDH)	(,L- , +) (Lactate	150
G6PD		2980
A09.05.042	(Alanine AminoTransferase, ALT, Serum Glutamic Pyruvic Transaminase, SGPT)	150
A09.05.045	(?- ,) (lpha- milase, ?-Amylase)	210

A09.05.180	(P-) (Pancreatic ?-Amylase)	250
	(S- , II, S-) (Cholinesterase, Pseudocholinesterase, PCHE)	230
A09.05.046	() (Alkaline Phosphatase, ALP)	150
A09.05.173	() (Lipase)	290
	() (Acid Phosphatase, ACP)	200
	(,) (Gamma-Glutamyl Transferase, GGT)	150
A09.05.043	(, ,) (Creatine Kinase, CK, Creatine Phosphokinase, CPK)	240
A09.05.041	(, , -) (Aspartateaminotransferase, AST, Serum Glutaminoxaloacetic Transaminase, SGOT)	150
	(- , - , -) (Creatine Kinase-MB, CK-MB, Creatine Phosphokinase-MB, CPK-MB.)	310
HLA-		
	HLA II (DRB1, DQA1, DQB1) (System Human Leukocyte Antigen (HLA) Class II, Typing (Genes DRB1, DQA1, DQB1))	5310
	(Genotype of RH factor Definition (without Description))	8880
	Y- (Y-chromosome of the fetus in the mother's blood)	4100
	(Rh factor Definition)	6200
	(Plasminogen)	600
	VIII () (Antihemophilic Globulin A, FVIII)	1030
A09.05.051.001	D- (D-Dimer)	1030
A09.05.050	(Fibrinogen, FG)	210
A12.05.039	() (Activated Partial Thromboplastin Time, APTT)	150
	IX, % (« ») Factor IX, Activity,% (Christmas Factor, anti-hemophilic globulin "B")	440
A12.05.027	(,), (Prothrombin, rothrombin Time, PT, International Normalized Ratio, INR)	230
A12.05.028	() (Thrombin Time, TT)	230
	() (Lupus Anticoagulant, LA)	730
	C, % (Protein C, % Activity)	1790
	/ (, /), Anti-Xa activity, IU/ml (Heparin concentration, IU/ml)	1670
	, % (Willebrand Factor, Antigen, %)	2030
A09.05.047	III, % (III, Antithrombin III, % Activity)	330
	S (Protein S, Free)	2220
	(Urine immunoglobulin free light chains (FLC) kappa and lambda)	1340
	(M-Gradient, Screening. Serum Protein Electrophoresis (SPEP), Immunofixation with Polyvalent Antiserum, Quantification of M-Protein (without Typing))	2160
	(Bence-Jones Protein, Urine, Electrophoresis, Immunofixation, Kappa/Lambda Typing, Quantification)	3000
A09.05.014	(Serum Protein Electrophoresis, SPE, SPE)*	250
	(IgG, IgA, IgM,), (M-Gradient, Typing. Serum Protein Electrophoresis (SPEP), Immunofixation with Antisera (IgG, IgA, IgM, Kappa, Lambda), Quantification of M-Protein)	3990
	(Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains)	1580

/		1960
	(Bence-Jones Protein, Urine, Immunofixation, Quantification)	1880
A09.05.011	(Albumin)	210
A09.05.010	(Protein Total)	150
A09.05.214	(Homocysteine)	1290
	(Urine Protein Electrophoresis)	1500
ImmunoCAP		
	(f216) IgE, ImmunoCAP	630
	(f33) IgE, ImmunoCAP	630
	, nArtv1 (w231) IgE, ImmunoCAP	1830
	(f9) IgE, ImmunoCAP	630
	(f260), IgE, ImmunoCAP (Broccoli, Brassica oleracea (f260), IgE, ImmunoCAP)	720
	(f26) IgE, ImmunoCAP	630
	() (i6) IgE, ImmunoCAP	630
	(f343), IgE, ImmunoCAP (Raspberry, Rubus idaeus, IgE, ImmunoCAP)	720
	(f35) IgE, ImmunoCAP	630
	, nGal d3 (f323) IgE, ImmunoCAP	830
	(Hollister-Stier) (hx2) IgE, ImmunoCAP	1250
	Candida albicans (m5) IgE, ImmunoCAP	630
	(i1) IgE, ImmunoCAP	630
	(i3) IgE, ImmunoCAP	630
	(c8) IgE, ImmunoCAP	630
	(f95) IgE, ImmunoCAP	630
	(f6) IgE, ImmunoCAP	720
	(Saccharomyces cerevisiae) (f45) IgE, ImmunoCAP	630
	, nGal d1 (f233) IgE, ImmunoCAP	830
	, rAra h 2 (f423) IgE, ImmunoCAP	1830
	, (e81) IgE, ImmunoCAP	630
	/ D. pter nyssinus (d1) IgE, ImmunoCAP	630
	, rBet v1/PR-10 (t215) IgE, ImmunoCAP	1830
	(f23) IgE, ImmunoCAP	630
	, nGal d2 (f232) IgE, ImmunoCAP	830
-	, (nBos d5) (f77) IgE, ImmunoCAP	830
-	(nBos d4) (f76) IgE, ImmunoCAP	830
	(f92) IgE, ImmunoCAP	630
	(f91) IgE, ImmunoCAP	630
	, (e6) IgE, ImmunoCAP	630
	, ImmunoCAP	2750
	, rGly m 4/PR-10 (f353) IgE, ImmunoCAP	1830
	, (e213) IgE, ImmunoCAP	630
	(f75) IgE, ImmunoCAP	630
	, (e1) IgE, ImmunoCAP	630
	, rAra h 1 (f422) IgE, ImmunoCAP	1830
	(Hollister -Stier) (h2) IgE, ImmunoCAP	630
	c, rAra h 9 LTP (f427) IgE, ImmunoCAP	1830

, rCan f 1 (e101) IgE, ImmunoCAP	1830
(f83) IgE, ImmunoCAP	630
(w5) IgE, ImmunoCAP	630
Malassezia spp. (m227) IgE, ImmunoCAP	630
, rCan f 2 (e102) IgE, ImmunoCAP	1830
/ (k80) IgE, ImmunoCAP	630
(f31) IgE, ImmunoCAP	630
(f14) IgE, ImmunoCAP	630
(Greer Labs.) (h1) IgE, ImmunoCAP	630
c (k82) IgE, ImmunoCAP	630
Cladosporium herbarum (m2) IgE, ImmunoCAP	630
(w8) IgE, ImmunoCAP	720
(mx2) IgE, ImmunoCAP	1250
(f24) IgE, ImmunoCAP	630
, rPen a1(f351) IgE, ImmunoCAP	1830
(f209) IgE, ImmunoCAP	630
(i71) IgE, ImmunoCAP	630
(f2) IgE, ImmunoCAP	630
() (f55) IgE, ImmunoCAP	630
(f210) IgE, ImmunoCAP	630
(f13) IgE, ImmunoCAP	630
, nArtv3 (w233) IgE, ImmunoCAP	1830
-5, rTri a 19 (f416) IgE, ImmunoCAP	1830
(fx15) IgE, ImmunoCAP	1250
, (e5) IgE, ImmunoCAP	630
(fx73) IgE, ImmunoCAP	1250
(fx5) IgE, ImmunoCAP	1250
(w204) IgE, ImmunoCAP	720
(f49) IgE, ImmunoCAP	630
Penicillium notatum (P.chrysogenum) (m1) IgE, ImmunoCAP	630
(f25) IgE, ImmunoCAP	630
, rCyp c 1 (f355) IgE, ImmunoCAP	1830
(i75) IgE, ImmunoCAP	630
(gx1) IgE, ImmunoCAP	1250
, rBet v2, rBet v4 (t221) IgE, ImmunoCAP	1830
(f11), IgE, ImmunoCAP	630
(m80) IgE, ImmunoCAP	630
Phadiatop ImmunoCAP, IgE	1570
, rPhl p1, rPhl p5 (g213) IgE, ImmunoCAP	1830
(f302) IgE, ImmunoCAP	720
, (nBos d8) (f78) IgE, ImmunoCAP	830
(mx1) IgE, ImmunoCAP	1250
V (c2) IgE, ImmunoCAP	630
(f227) IgE, ImmunoCAP	720
(tx9) IgE, ImmunoCAP	1250
(f12), IgE, ImmunoCAP (Pea, Pisum sativum, IgE, ImmunoCAP)	720

(f20) IgE, ImmunoCAP	720
() (f212), IgE, ImmunoCAP (Mushrooms, Agaricus hortensis, IgE, ImmunoCAP)	720
/ D. farina (d2) IgE, ImmunoCAP	630
(f88) IgE, ImmunoCAP	630
(f94), IgE, ImmunoCAP (Pear, Pyrus communis, IgE, ImmunoCAP)	720
(f17) IgE, ImmunoCAP	630
(f4) IgE, ImmunoCAP	630
(f208) IgE, ImmunoCAP	630
, nBos d6 BSA (e204) IgE, ImmunoCAP	1830
(f262), IgE, ImmunoCAP (Eggplant, Solanum melongena, IgE, ImmunoCAP)	720
(f221), IgE, ImmunoCAP (Coffee, Coffea spp., IgE, ImmunoCAP)	720
(f222) IgE, ImmunoCAP	720
(wx1) IgE, ImmunoCAP	1250
(f322) IgE, ImmunoCAP	720
(f93) IgE, ImmunoCAP	630
, rPhl p7, rPhl p12 (g214) IgE, ImmunoCAP	1830
, rFel d1 (e94) IgE, ImmunoCAP	1830
(f27) IgE, ImmunoCAP	630
(f84) IgE, ImmunoCAP	630
, nGal d4 (k208) IgE, ImmunoCAP	830
, nAmb a1 (w230) IgE, ImmunoCAP	1830
(w6) IgE, ImmunoCAP	630
(f48), IgE, ImmunoCAP (Onion, Allium cepa, IgE, ImmunoCAP)	720
G (c1) IgE, ImmunoCAP	630
(g6) IgE, ImmunoCAP	630
(t3) IgE, ImmunoCAP	630
, rFel d2 (e220) IgE, ImmunoCAP	1830
B (m81) IgE, ImmunoCAP	630
(f237), IgE, ImmunoCAP (Apricot, Prunus armeniaca, IgE, ImmunoCAP)	720
(f242), IgE, ImmunoCAP (Cherry, Prunus avium, IgE, ImmunoCAP)	720
Ig E ImmunoCAP	690
TSST (m226) IgE, ImmunoCAP	630
Alternaria alternata (m6) IgE, ImmunoCAP	630
Aspergillus fumigatus (m3) IgE, ImmunoCAP	630
(f47) IgE, ImmunoCAP	720
Phadiatop Infant ImmunoCAP, IgE	1990
, rAra h 3 (f424) IgE, ImmunoCAP	1830
(f1) IgE, ImmunoCAP	630
c (f7) IgE, ImmunoCAP	630
c, rAra h 8/PR-10 (f352) IgE, ImmunoCAP	1830
(f85) IgE, ImmunoCAP	630
, (f44) IgE, ImmunoCAP	630
(f225) IgE, ImmunoCAP	630
(i2) IgE, ImmunoCAP	630
(f300) IgE, ImmunoCAP	720
(f3) IgE, ImmunoCAP	630

(e85) IgE, ImmunoCAP	630
, nCan f3 (e221) IgE, ImmunoCAP	1830
(w206) IgE, ImmunoCAP	720
Alternaria alternata, rAlt a 1 (m229) IgE, ImmunoCAP	1830
HLA-B27 (Molecular Genetic Testing HLA-B27)	1550
() (Anti- cyclic Citrullinated Peptide, anti-CCP)	1320
IgG (Anti- eratin ntibodies, AKA, Anti-Filaggrin ntibodies, AFA, IgG)	2040
, IgA (IgA; Rheumatoid Factor, RF, IgA)	1120
() (Synovial Fluid Smear, Crystals)	1550
IgG (-M) (Anti-Mutated Citrullinated Vimentin Antibodies, Anti-MCV, Anti-Modified Citrullinated Vimentin Antibodies, Anti-Sa Antibodies, IgG)	1380
(CMV DNA, Scrape of Nasal Epithelial Cells)*	250
(CMV DNA, Scrape of Faucial Epithelial Cells)*	250
(CMV DNA, Blood)*	380
(CMV DNA, Exudate)*	250
(CMV DNA, Serum)*	380
A IgM (Anti-CMV IgM)	490
(CMV DNA, Prostatic Fluid, Semen)*	250
(CMV DNA, Scrape of Skin Epithelial Cells)*	250
(CMV DNA, Urine)*	250
(CMV DNA, Scrape of Urogenital Epithelial Cells)*	250
(CMV DNA, Saliva)*	250
(Cytomegalovirus, DNA)	370
Anti-CMV IgG	1040
A IgG (Anti-CMV IgG)	360
(CMV DNA, Scrape of Conjunctiva Epithelial Cells)*	250
(CMV DNA, Cerebrospinal Fluid)*	250
(Copper, random urine; Cu)	1180
(Cd) (Cadmium (Cd), Urine)	1180
(Co) (Cobalt (Co), Urine)	1180
(Tl) (Thallium (Tl), Urine)	1180
(I) (Iodine (I), Urine)	1180
(Mn) (Manganese (Mn), Urine)	1180
(Fe) (Iron (Fe), Urine)	1180
(Hg) (Mercury (Hg), Urine)	1180
(Al) (Aluminum (Al), Urine)	1180
()	680
(Zn) (Zinc (Zn), Urine)	1180
(Cu) (Copper (Cu), 24-Hours Urine)	1180

(Ni)	(Nickel (Ni), Urine)	1180
(Se)	(Selenium (Se), Urine)	1180
	()	680
(Pb)	(Lead (Pb), Urine)	1180
(As)	(Arsenic (As), Urine)	1180

IgG	(anti-Tetanus toxoid IgG)	900
-----	----------------------------	-----

(Ni)	(Nickel (Ni), Serum)	250
(Hg)	(Mercury (Hg), blood)	1180
	()	680
(As)	(Arsenic (As), Serum)	250
(Cd)	(Cadmium (Cd), Serum)	250
(Co)	(Cobalt (Co), Serum)	250
(Ni)	(Nickel (Ni), blood)	1180
(Zn)	(Zinc (Zn), blood)	1180
	(Iodine, serum)	250
(Au)	(Gold (Au), Serum)	250
(Cu)	(Copper (Cu), Serum)	250
	()	680
(Cu)	(Copper (Cu), blood)	1180
(Pb)	(Lead (Pb), blood)	1180
(Mn)	(Manganese (Mn), blood)	1180
(Zn)	(Zinc (Zn), Serum)	250
(Li)	(Lithium (Li), serum)	250
(Cd)	(Cadmium (Cd), blood)	1180
(Se)	(Selenium (Se), Serum)	250
(Se)	(Selenium (Se), blood)	1180
(Mn)	(Manganese (Mn), Serum)	250
(Co)	(Cobalt (Co), blood)	1180
	(3 , Reverse Triiodthyronine).	5970
(Tl)	(Thallium (Tl), Serum)	250
	(())	680
(Mo)	(Molybdenum (Mo), Serum)	250

ATM (FISH,) (Analysis of ATM gene rearrangements (FISH, quantitative))		9850
MPL, (Analysis of MPL gene mutations, PCR, qualitative)		4390
BCL- 6 (der(3)(q27)) (FISH,) (Analysis of BCL- 6 gene rearrangements (der(3)(q27)) on paraffin slides (FISH Histology, quantitative))		13570
MLL/AF4 -t(4;11) (,) (Analysis of chimeric gene MLL/AF4 -t(4;11) (PCR, qualitative))		2260
BCL- 6 (der(3)(q27)) (FISH,) (Analysis of BCL- 6 gene rearrangements (der(3)(q27) (FISH, quantitative))		9850
13 - (del(13), -13) (FISH,) (Analysis of chromosome 13 monosomy, deletion - (del(13), -13) (FISH, quantitative))		9850
53 (FISH,) (Analysis of 53 gene deletion (FISH, quantitative))		9850
t(2;5)(p23;q35) (FISH,) (Analysis of translocation t(2;5)(p23;q35) on paraffin slides (FISH Histology, quantitative))		13570

(FISH, .) (Analysis of all specific aberrations on paraffin slides (FISH Histology, quantitative))	13570
t(11;14)(q13;q32) (FISH, .) (Analysis of translocation t(11;14)(q13;q32) on paraffin slides (FISH Histology, quantitative))	13570
t(11;14)(q13;q32) (FISH, .) (Analysis of translocation t(11;14)(q13;q32) (FISH,quantitative))	9850
PML/RAR? -t(15;17) (, .) (Analysis of chimeric gene PML/RAR? -t(15;17) (PCR, qualitative))	2260
CBF?/MYH1- inv(16),t(16;16) (, .) (Analysis of chimeric gene CBF?/MYH1- inv(16),t(16;16) (PCR, qualitative))	2260
12 (+12) (FISH, .) (Analysis of chromosome 12 trisomy (FISH, quantitative))	9850
V617F 14 JAK2 (Qualitative assessment of presence of gene JAK2 617F somatic mutation)	1770
t(11;18)(q21;q21) (FISH, .) (Analysis of translocation t(11;18)(q21;q21) (FISH, quantitative))	9850
(Karyotype, Hematologic Disorders, Peripheral Blood)	7020
53 (FISH, .) (Analysis of 53 gene deletion (FISH, quantitative))	9850
t(14;16) (IGH/MAFB) (FISH, .) (Analysis of translocation t(14;16) (IGH/MAFB) (FISH,quantitative))	9850
BCR/ABL - t(9;22), BCR/ABL - . (Analysis of chimeric gene BCR-ABL - t(9;22), assessment of the BCR-ABL gene transcript type, PCR, qualitative)	2260
12p (FISH, .) (Analysis of 12p deletion (FISH, quantitative))	9850
BCR-ABL (FISH, .) (Analysis of chimeric gene BCR-ABL, FISH, quantitative)	9850
BCL2 (FISH, .) (Analysis of BCL2 gene rearrangements on paraffin slides (FISH Histology, quantitative))	13570
PDGFR?(FISH, .) (Analysis of gene rearrangements PDGFR? (FISH, quantitative))	9850
FGFR1 (FISH, .) (Analysis of gene rearrangements FGFR1 (FISH, quantitative))	9850
E2A/PBX1 - t(1;19) (, .) (Analysis of chimeric gene E2A/PBX1 - t(1;19) (PCR, qualitative))	2260
BRAF (V600E) (, .)	7790
5 (FISH, .) (Analysis of chromosome 5 rearrangements (FISH, quantitative))	9850
t(4;14)(p16;q32) (FISH, .) (Analysis of translocation t(4;14)(p16;q32) (FISH, quantitative))	9850
t(14;16) (IGH/MAFB) (FISH, .) (Analysis of translocation t(14;16) (IGH/MAFB) (FISH,quantitative))	9850
BCR/ABL - RQ (, .) (Analysis of the BCR/ABL relative expression, RQ-PCR, quantitative)	4390
() (Cytogenetic analysis of bone marrow (karyotype))	7020
FIP1L1/PDGFR?(FISH, .) (Analysis of chimeric gene FIP1L1/PDGFR? (FISH, quantitative))	9850
MLL (FISH, .) (Analysis of MLL gene rearrangements (FISH, quantitative))	9850
7 (FISH, .) (Analysis of chromosome 7 rearrangements (FISH, quantitative))	9850
13 - (del(13), -13) (FISH, .) (Analysis of chromosome 13 monosomy, deletion - (del(13), -13) (FISH,quantitative))	9850
12 JAK2 (, .) (Analysis of JAK2 Exon 12 mutations (PCR qualitative))	4390
BCL2 t(14;18)(q32;q21),t(2;18)(p11;q21),t(18;22)(q21;q11) (FISH, .) (Analysis of BCL2 gene rearrangements t(14;18)(q32;q21),t(2;18)(p11;q21),t(18;22)(q21;q11) (FISH, quantitative))	9850
BCR-ABL (, .) (BCR-ABL1 Mutation Analysis using direct Sanger sequencing, qualitative)	8760
1 (FISH, .)	12970
3q (FISH, .) (Analysis of 3q rearrangements (FISH, quantitative))	9850
RUNX1/RUNX1T1 -t(8;21) (, .) (Analysis of chimeric gene RUNX1/RUNX1T1 -t(8;21) (PCR, qualitative))	2260
20q (FISH, .) (Analysis of 20q deletion (FISH, quantitative))	9850

MYC (t(8;14)(q24;q32)-t(2;8)(p11;q24), t(8;22)(q24;q11)) (FISH, quantitative)		9850
deletions, insertions, PCR, qualitative)	CALR () (Analysis of CALR gene mutations,	4390
quantitative))	IGH (FISH,) (Analysis of IGH gene rearrangements (FISH,	9850
quantitative))	t(2;5)(p23;q35) (FISH,) (Analysis of translocation t(2;5)(p23;q35) (FISH,	9850
:		
		1200
participant (child or mother or father)	() (Additional research	5730
(3) (Urgent Establishment of Biological Relationship for One Parent at Indisputable Relationship of Another (3 Persons))		38030
(2) (Urgent Establishment of Biological Relationship for One Parent in Absence of Another (2 Persons))		38030
(2) (Establishment of Biological Relationship for One Parent in Absence of Another (2 Persons))		16170
(3) (Establishment of Biological Relationship for One Parent at Indisputable Relationship of Another (3 Persons))		18080
:		
(Koprogramma, Stool)		340
		3690
		5570
(Fecal Calprotectin)		2380
		3220
-1- (Alpha-1-Antitrypsin, Feces)		1570
		1330
		230
() (PRO Stool, Helminth Eggs)		280
		1800
FOB Gold (Quantitative Immunochemical Fecal Occult Blood, Test FOB Gold)		650
1 (1), 1 (Elastase 1, E1)		2520
() (Stool Sugars, Reducing Substances, Fecal)		560
(PRO Stool)		280
(), (nterobiasis, Spatula)		260
(Stool osmotic gap)		1150
:		
-10 (-10) (Interleukin 10, IL-10)		1850
-6 (-6) (Interleukin 6, IL-6)		1850
-? (-?) (Tumor Necrosis Factor Alpha, TNF-?, Cachectin)		1850
-1? (-1?) (Interleukin 1 Beta, IL-1)		1850
-8 (-8) (Interleukin 8, IL-8)		1850
IgE:		
, IgE (Food Allergy Panel, IgE)		3670
, IgE (Celery, IgE, F85)		440
, IgE (Milk, IgE, F2)		440
(f96), IgE, ImmunoCAP (Avocado, Persea americana, IgE, ImmunoCAP)		720

, IgE (Chicken Meat, IgE, F83)	440
(f244) IgE, ImmunoCAP	720
, IgE (Pineapple, IgE, F210)	440
, IgE (Grapefruit, IgE, F209)	440
- , IgE (Beta Lactoglobulin, IgE, F77)	440
, IgE (Egg Yolk, IgE, F75)	440
(g4) IgE, ImmunoCAP	720
, IgE (Shrimp, IgE, F24)	440
, IgE (Rice, IgE, F9)	440
, IgE (Strawberry, IgE, F44)	440
, IgE (Apple, IgE, F49)	440
, IgE (Pork, IgE, F26)	440
, IgE (Lamb, IgE, F88)	440
, IgE (Tomato, IgE, F25)	440
, IgE (Baker's Yeast, IgE, F45)	440
, IgE (Potato, IgE, F35)	440
, IgE (Lemon, IgE, F208)	440
, IgE (Peach, IgE, F95)	440
3: , IgE (FP73 (F26, F27, F83, F88), Food Panel: Pork, Beef, Chicken Meat, Lamb, IgE)*	950
" 2"	1745
, IgE (Casein, IgE, F78)	440
, IgE (Kiwi Fruit, IgE, F84)	440
, IgE (Cabbage, IgE, F216)	440
, IgE (Codfish, IgE, F3)	440
, IgE (Wheat, IgE, F4)	440
1: , IgE (FP15 (F33, F49, F92, F95), Food Panel: Orange, Banana, Apple, Peach, IgE)*	950
, IgE (Carrot, IgE, F31)	440
, IgE (Common Millet, IgE, F55)	440
, IgE (Banana, IgE, F92)	440
, IgE (Soybean, IgE, F14)	440
, IgE (Chocolate, IgE, F105)	440
, IgE (Egg White, IgE, F1)	440
2: , IgE (FP50 (F84, F91, F92, F210), Food Panel: Kiwi Fruit, Mango, Banana, Pineapple, IgE)*	950
, IgE (Pumpkin, IgE, F225)	440
, IgE (Hazelnut, IgE, F17)	440
, IgE (Orange, IgE, F33)	440
, (e3) IgE, ImmunoCAP	720
(f329), IgE, ImmunoCAP (Watermelon, Citrullus lanatus, IgE, ImmunoCAP)	720
(f5) IgE, ImmunoCAP	720
, IgE (Beef, IgE, F27)	440
, IgE (Oat, IgE, F7)	440
" 1"	1745
, IgE (Buckwheat, IgE, F11)	440
, IgE (Brewer's Yeast, IgE, F403)	520
, IgE (Crab, IgE, F23)	440

	, IgE (Peanut, IgE, F13)		440
	, IgE (Mango, IgE, F91)		440
(Ca)	(Calcium (Ca), air)		1180
(Co)	(Cobalt (Co), air)		1180
(Zr)	(Zirconium (Zr), air)		1180
(Mg)	(Magnesium (Mg), air)		1180
(Be)	(Beryllium (Be), air)		1180
(Pb)	(Lead (Pb), air)		1180
(Mo)	(Molybdenum (Mo), air)		1180
(Al)	(Aluminum (Al), air)		1180
(Hg)	(Mercury (Hg), air)		1180
(Mn)	(Manganese (Mn), air)		1180
(Se)	(Selenium (Se), air)		1180
(V)	(Vanadium (V), air)		1180
(Si)	(Silica (Si), air)		1180
(Rb)	(Rubidium 9Rb), air)		1180
(Bi)	(Bismuth (Bi), air)		1180
(P)	(Phosphorus (P), air)		1180
	()		680
(Cu)	(Copper (Cu), air)		1180
(Sb)	(Antimony (Sb), air)		1180
(I)	(Iodine (I), air)		1180
(Ba)	(Barium (Ba), air)		1180
(B)	(Boron (B), air)		1180
(La)	(Lanthanum 9La), air)		1180
(Fe)	(Iron (Fe), air)		1180
(Ag)	(Silver (Ag), air)		1180
(Cr)	(Chromium (Cr), air)		1180
(Sr)	(Strontium (Sr), air)		1180
(W)	(Tungsten, Wolframium (W), air)		1180
(Na)	(Sodium (Na), air)		1180
(Pt)	(Platinum (Pt), air)		1180
(Ge)	(Germanium (Ge), air)		1180
(As)	(Arsenic (As), air)		1180
(Cd)	(Cadmium (Cd), air)		1180
(K)	(Potassium (K), air)		1180
(Ni)	(Nickel (Ni), air)		1180
(Zn)	(Zinc (Zn), air)		1180
(Sn)	(Tin (Sn), air)		1180
(Li)	(Lithium (Li), air)		1180
(Au)	(Gold (Au), air)		1180
(Tl)	(Thallium (Tl), air)		1180
(Ga)	(Gallium (Ga), air)		1180

IgG () (Extractable Nuclear Antigen, ENA, Anti-Ribonucleoprotein Antibodies, Anti-RNP)	1120
(Scl-70, ENP-A, CENP-B, RP11, RP155, NOR90, Th/To, PM-Sc100, PM-Sc175, Ku, PDGFR, Ro-52), (Scleroderma (Systemic Sclerosis) Antibody Panel: Anti-Scl-70, ENP-A, CENP-B, RP11, RP155, NOR90, Th/To, PM-Sc100, PM-Sc175, Ku, PDGFR, Ro-52, Immunoblotting)	4010
(), (Anti-Nuclear Antibodies, ANA, Screening)	470
(, HEp-2 (, HEp-2) (Antinuclear Antibodies, ANA, Hep-2 Substrate, ANA-Hep2, Fluorescent Anti-Nuclear Antibodies detection, FANA, iters)	1150
(Sm, RNP/Sm, SS-A (60), SS-A (52), SS-B, Scl-70, PM-Sc1, PCNA, CENT-B, dsDNA, Histone, Nucleosome, Rib P, AMA-M2, Jo-1), (ANA: Anti-Sm, RNP/Sm, SS-A (60 kD), SS-A (52 kD), SS-B, Scl-70, PM-Sc1, PCNA, CENT-B, dsDNA, Histone, Nucleosome, Rib P, AMA-M2, Anti-Jo-1, Immunoblotting)	3190
IgG (a), (Anti-Nuclear Antibodies, ANA, IgG, Screening)	1120
(,)	990
IgG (- IgG, -) (Double-Stranded (Native) DNA IgG Antibodies, nti-dsDNA IgG)	570
(, IgG)	1570

B03.016.014 (Nechiporenko's Urine Test)	230
() (Sulkowitch Urine Calcium Test)	130
B03.016.006 (Complete Urinalysis, Microscopic Examination)	230

(, Hepatitis C Virus, HCV)

(Hepatitis C Virus (HCV) RNA, Quantitative PCR, Genotyping (Types 1, 2, 3)) (1, 2, 3)	3680
-28 (-28), () (Interleukin 28 Beta IL28B, Genotyping (Study of Genetic Markers Determining Effectiveness of Treatment of Chronic Hepatitis C in Interferon and Ribavirin))	720
(CITO), (HCV RNA, Plasma, Quantitative)*	20940
(), (Hepatitis C Virus (HCV) RNA, Ultrasensitive PCR)	3050
IgM IgG (Anti-HCV Total (IgG + IgM))*	360
IgG C, (Anti-HCV IgG, Immunoblot)	5110
(HCV RNA, Serum, Qualitative)*	630
(HCV RNA, Serum, Quantitative, PCR)*	3140
(1 (1a 1b), 2, 3) (Hepatitis C Virus (HCV) RNA, Plasma, Genotyping, Subtypes (Types 1 (Subtypes 1a, 1b), 2, 3))*	840
(HCV RNA, Plasma, Quantitative)*	10470

(, Staphylococcus aureus)

(Staphylococcus aureus), (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)	980
(Staphylococcus aureus), (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)	1950
(Staphylococcus aureus) (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus – MRSA) Culture. Bacteria Identification)	650
(Staphylococcus aureus, (Staphylococcus aureus Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)	980

(Staphylococcus aureus), (Staphylococcus aureus Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)		1950
(Staphylococcus aureus) (Staphylococcus aureus Culture. Bacteria Identification)		650
(Staphylococcus aureus), (Staphylococcus aureus Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		800
(Staphylococcus aureus), (Staphylococcus aureus (Methicillin-Resistant Staphylococcus aureus - MRSA) Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		800
(- 1 2 , Herpes simplex virus, HSV-1, HSV-2)		
1 2 , (HSV-1, 2 DNA, Urine)*		250
1 2 , Serum, yping)* (HSV-1, 2 DNA,		600
1 2 , (HSV-1, 2 DNA, Scrape of Conjunctiva Epithelial Cells)*		250
1 2 , (HSV-1, 2 DNA, Scrape of Conjunctiva Epithelial Cells, yping)*		420
1 2 , (HSV-1, 2 DNA, Urine, yping)*		420
IgG 1 2 (Anti-HSV-1, 2 IgG)		440
1 2 , Blood, yping)* (HSV-1, 2 DNA,		600
1 2 , 2 DNA, Cerebrospinal Fluid, yping)* (HSV-1,		420
1 2 , (HSV-1, 2 DNA, Exudate)*		250
1 2 , (HSV-1, 2 DNA, Scrape of Faucial Epithelial Cells, yping)*		420
Ig 1 2 (Anti-HSV-1, 2 Ig)		460
1 2 , (HSV-1, 2 DNA, Scrape of Urogenital Epithelial Cells, yping)*		420
1 2 , yping)* (HSV-1, 2 DNA, Saliva,		420
1 2 , yping)* (HSV-1, 2 DNA, Exudate,		420
1 2 , (HSV-1, 2 DNA, Blood)*		380
1 2 , (HSV-1, 2 DNA, Saliva)*		250
1 2 , DNA, Scrape of Skin Epithelial Cells)* (HSV-1, 2		250
1 2 , (HSV-1, 2 DNA, Scrape of Nasal Epithelial Cells, yping)*		420
1 2 , Cerebrospinal Fluid)* (HSV-1, 2 DNA,		250
1 2 , Prostatic Fluid, Semen)* (HSV-1, 2 DNA,		250
1 2 , 2 DNA, Prostatic Fluid, Semen, yping)* (HSV-1,		420
IgG 2 (Anti-HSV-2 IgG)		550
1 2 , (HSV-1, 2 DNA, Serum)*		380
1 2 , (HSV-1, 2 DNA, Scrape of Nasal Epithelial Cells)*		250
Anti-HSV IgG		700
1 2 , (HSV-1, 2 DNA, Scrape of Urogenital Epithelial Cells)*		250
1 2 , (HSV-1, 2 DNA, Scrape of Skin Epithelial Cells, yping)*		420
IgG 1 (Anti-HSV-1 IgG)		680
1 2 , (HSV-1, 2 DNA, Scrape of Faucial Epithelial Cells)*		250
COVID-19		
SARS-CoV-2, IgM (anti-SARS-CoV-2, IgM)		690

SARS-CoV-2-IgG- (N-, S-proteins) antibodies, IgG, qualitative)	SARS-CoV-2 (N-, S-), (Post-vaccination (EpiVacCorona Vector) SARS-CoV-2	2260
SARS-CoV-2, (Coronavirus SARS-CoV-2 RNA detection in nasopharyngeal and oropharyngeal smear)		1990
spike (S) protein (RBD), IgG, quantitative).	(S) (RBD) SARS-CoV-2, IgG (Anti-SARS-CoV-2,	1290
SARS-CoV-2, (Coronavirus SARS-CoV-2 RNA detection in nasopharyngeal and oropharyngeal smear)		1290
SARS CoV-2 (S- RBD), IgG,		1290
(S) SARS-CoV-2, IgG, (anti-SARS-CoV-2 S (spike) protein antibody, IgG, qualitative. Assessment of immunity before and after vaccination)		890
SARS-CoV-2 (nucleocapsid protein), IgG, Abbott)	(Anti-SARS-CoV-2	690
SARS-CoV-2 (RBD), IgG (anti-SARS-CoV-2 (RBD) IgG avidity)		690

A IgM Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgM)		500
(Mycoplasma genitalium), (Mycoplasma genitalium, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Mycoplasma hominis), (Mycoplasma hominis, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Mycoplasma pneumoniae), (Mycoplasma pneumoniae, DNA, Plasma)*		390
Ig Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgA)		610
(Mycoplasma pneumoniae), (Mycoplasma pneumoniae, DNA, Scrape of Faucial Epithelial Cells)*		210
A IgG Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgG)		500
Ig Mycoplasma hominis (Anti-Mycoplasma hominis Ig)		420
(Mycoplasma pneumoniae), (Mycoplasma pneumoniae, DNA, Sputum)*		590
(Mycoplasma hominis), (Mycoplasma hominis, DNA, Prostatic Fluid, Semen)*		250
IgG Mycoplasma hominis (Anti-Mycoplasma hominis IgG)		420
(Mycoplasma genitalium), (Mycoplasma genitalium, DNA, Prostatic Fluid, Semen)*		250
(Mycoplasma pneumoniae), (Mycoplasma pneumoniae, DNA, Saliva)*		210
(Mycoplasma hominis), (Mycoplasma hominis, DNA, Urine)*		250
IgA Mycoplasma hominis (Anti-Mycoplasma hominis IgA)		610
(Mycoplasma genitalium), (Mycoplasma genitalium, DNA, Urine)*		250

(g) (Magnesium (Mg), Serum)		230
(Ca) (Calcium Total)		190
/ / (+/Potassium, Na+ /Sodium, I-/Chloride, Serum)		250
(Ca ²⁺ , c) (Ionized Calcium, Free Calcium)		360
(P) (Phosphorus (P))		190
() (Unsaturated Iron Binding Capacity, UIBC)		190
A09.05.007 (Fe) (Iron (Fe), Serum)		190

Associated Gastritis)* Helicobacter pylori (Helicobacter pylori		3640
PDGFRa		13700
1 () (1):		1540

PD-L1 SP263 (Ventana). (PD-L1 expression in tumor tissue by IHC using PD-L1 clone SP263 (Ventana) antibodies).	16500
KIT	11600
Finished Histological Preparations (1 Glass + 1 Block)	1300
BRCA1, BRCA2	7400
(PAS-)	290
ROS1	8000
18, 19, 20, 21 EGFR	9900
2, 3, 4 NRAS	7000
15 BRAF	4800
2, 3, 4 KRAS	7000
PD-L1 SP142 (Ventana). (PD-L1 expression in tumor tissue by IHC using PD-L1 clone SP142 (Ventana) antibodies).	16500
(MSI)	6200
HER2 ()	11600
S-100, Melan A (MART-1), HMB-45, SOX-10 (IHC verification of malignant melanoma using assessment of the expression S-100, Melan A (MART-1), HMB-45, SOX-10)*	18080
() (Pathology of skin biopsies)*	2030
Histochemical Study)* Helicobacter pylori () (Helicobacter pylori, Mucus,	1920
ALK	8000
(; ; ; -)*	2200
PD-L1 22C3 (Dako). (PD-L1 expression in tumor tissue by IHC using PD-L1 clone 22C3 (Dako) antibodies).	24000
PDL1	7400
S-100, Melan A (MART-1), HMB-45, SOX-10 (IHC verification of malignant melanoma using assessment of the expression S-100, Melan A (MART-1), HMB-45, SOX-10)	18080
SCC () (Squamous Cell Carcinoma Antigen, SCCA, SCCAg)	2260
-19-9 (19-9) (Carbohydrate Antigen -19-9, Cancer Antigen-GI)	620
(Chromogranin A, CgA)	4770
() (Carcinoembryonic Antigen, CEA)	570
CA-242 (242, CA-242) (Carbohydrate Antigen -242, Tumor Marker CA-242)	840
ROMA1	70
() (Neuron-Specific Enolase, NSE)	1220
PSA Total)* () (Prostate-Specific Antigen Total,	440
UBC (8 18) (Urine Bladder Cancer Antigen, Urine Bladder Cancer, UBC)	1860
(, , -2proPSA, phi)	2900
HE4 (4) (Human Epididymis Protein 4, HE4)	1020
-2- Serum) (?-2-) (eta-2-Microglobulin, BMG,	870
PSA Total) () (Prostate-Specific Antigen Total,	440
ROMA2	70
- () (?-Fetoprotein, AFP)	350

-15-3 (15-3) (Carbohydrate Antigen -15-3, Cancer Antigen -15-3)	620
-125 (125) (Carbohydrate Antigen -125, Cancer Antigen -125)	580
()*	440
CA-72-4 (72-4) (Carbohydrate Antigen -72-4, Cancer Antigen CA-72-4)	870
(Cyfra 21-1, 19) (Cytokeratin 19 Fragments, C-terminus of Cytokeratin 19, CK19 Soluble Fragments, Cyfra 21-1)	860
-2- (?-2-) (Beta-2-Microglobulin, Urine)	870
S100 (S100 rotein)	2490
()	
(Trichomonas vaginalis, DNA, Urine)*	250
Prostatic Fluid, Semen)* (Trichomonas vaginalis, DNA,	250
(Trichomonas vaginalis, DNA, Scrape of Urogenital Epithelial Cells)*	250
IgG Trichomonas vaginalis (nti-Trichomonas vaginalis IgG)	610
(Procedural services)	
(Blood serum derivation without further examinations)**	320
	350
(Blood sampling without further examinations)**	190
(Buccal epithelium sampling, 2 persons)	180
(Cytological material sampling, PCR diagnosis material sampling, microbiology test material sampling)	350
(Saliva sampling for PCR)	50
A11.12.009	200
(Biomaterial sampling for the enterobiasis test)	70
(Buccal epithelium sampling, 3 persons)	270
() (capillary blood sampling)	190
(Buccal epithelium sampling)	90
C	
6 (1 ,1b,2,3 ,4,5 ,6)	2380
(Ureaplasma parvum, Effectiveness Monitoring of Treatments) (Ureaplasma parvum)	360
(INBIOFLOR ? Mycoplasma, Urogenital Screening) ()	480
(INBIOFLOR-Comprehensive Study of Microflora Composition of Urogenital Tract (UGT))	2780
(Bacterial Vaginosis, BV)	1540
MICROBIOCENOSIS (PCR Panel Femoflor 8) 8. (UROGENITAL TRACT)	1480
(4 +): Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, (Identification of Sexually Transmitted Infections (STI) Pathogens, Chlamydia trachomatis DNA, Neisseria gonorrhoeae DNA, Trichomonas vaginalis DNA, Mycoplasma genitalium DNA, Human DNA)	930
(Mobiluncus curtisii, DNA, Scrape of Urogenital Epithelial Cells)	210
(Mycoplasma hominis, Effectiveness Monitoring of Treatments) (Mycoplasma hominis)	360
	1700
(Ureaplasma ur alyticum) (Ureaplasma ur alyticum, Effectiveness Monitoring of Treatments)	360
(7 +), (Identification of Sexually Transmitted Infections (STI) Pathogens, Scrape of Urogenital Epithelial Cells)*	1350

MICROBIOCENOSIS (PCR Panel Femoflor 16))	16. (UROGENITAL TRACT	2100
		2000
MICROBIOCENOSIS, Screening (PCR Panel Femoflor Screen))	(UROGENITAL TRACT	1850
		1240
		3820
(As)	(Arsenic (As), Nails)	1180
(Pb)	(Lead (Pb), Nails)	1180
(Sb)	(Antimony (Sb), Nails)	1180
(Cr)	(Chromium (Cr), Nails)	1180
(Sn)	(Tin (Sn), Nails)	1180
(Hg)	(Mercury (Hg), Nails)	1180
(Fe)	(Iron (Fe), Nails)	1180
(Cd)	(Cadmium (Cd), Nails)	1180
(Ge)	(Germanium (Ge), Nails)	1180
(Mo)	(Molybdenum (Mo), Nails)	1180
(P)	(Phosphorus (P), Nails)	1180
	()	680
(V)	(Vanadium (V), Nails)	1180
(Bi)	(Bismuth (Bi), Nails)	1180
(Ca)	(Calcium (Ca), Nails)	1180
(La)	(Lanthanum (La), Nails)	1180
(Cu)	(Copper (Cu), Nails)	1180
(Al)	(Aluminum (Al), Nails)	1180
(Au)	(Gold (Au), Nails)	1180
(Ga)	(Gallium (Ga), Nails)	1180
(Se)	(Selenium (Se), Nails)	1180
(Li)	(Lithium (Li), Nails)	1180
(Zn)	(Zinc (Zn), Nails)	1180
(B)	(Boron (B), Nails)	1180
(Ba)	(Barium (Ba), Nails)	1180
(I)	(Iodine (I), Nails)	1180
(Be)	(Beryllium (Be), Nails)	1180
(K)	(Potassium (K), Nails)	1180
(Co)	(Cobalt (Co), Nails)	1180
(W)	(Tungsten, Wolframium (W), Nails)	1180
(Tl)	(Thallium (Tl), Nails)	1180
(Si)	(Silica (Si), Nails)	1180
(Ni)	(Nickel (Ni), Nails)	1180
(Mg)	(Magnesium (Mg), Nails)	1180
(Sr)	(Strontium (Sr), Nails)	1180
(Rb)	(Rubidium (Rb), Nails)	1180
(Na)	(Sodium (Na), Nails)	1180
(Mn)	(Manganese (Mn), Nails)	1180
(Ag)	(Silver (Ag), Nails)	1180

(Zr)	(Zirconium (Zr), Nails)	1180
(Pt)	(Platinum (Pt), Nails)	1180
24-h urine)	, 24- (Estrogens and progesterone metabolites,	6100
	(Melatonin, plasma)	2400
	()	1340
39, 45, 51, 52, 56, 58, 59, 66, 68 + , o	14 : 16, 18, 31, 33, 35, (HPV DNA, Scrape of Rectal Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*	350
, o	4 : 6, 11, 16, 18 + (HPV DNA, Scrape of Urogenital Epithelial Cells, 4 Types (6, 11, 16, 18) Screening)	550
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 +	14 : 16, (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68))	350
39, 45, 51, 52, 56, 58, 59, 66, 68 + , o	14 : 16, 18, 31, 33, 35, (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*	350
Epithelial Cells, 3 Types (6, 11, 44)	3 : 6, 11, 44 + (HPV DNA, Scrape of Rectal	350
Epithelial Cells, 2 Types (16, 18))	16 18 + (HPV DNA, Scrape of Urogenital	350
(6, 11, 44))	3 : 6, 11, 44 (HPV DNA, Scrape of Faucial Epithelial Cells, 3 Types	350
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 +	() 14 : 16, 18, (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)	900
Epithelial Cells, 3 Types (6, 11, 44)	3 : 6, 11, 44 + (HPV DNA, Scrape of Urogenital	350
39, 45, 51, 52, 56, 58, 59, 66, 68 + , o	14 : 16, 18, 31, 33, 35, (HPV DNA, Scrape of Faucial Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*	350
52, 53, 56, 58, 59, 66, 68, 73, 82 + , o	21 : 6, 11, 16, 18, 26, 31, 33, 35, 39, 44, 45, 51, (HPV DNA, Scrape of Urogenital Epithelial Cells, 21 Types (6, 11, 16, 18, 26, 31, 33, 35, 39, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82))	2450
39, 45, 51, 52, 56, 58, 59, 66, 68 + , o	14 : 16, 18, 31, 33, 35, (HPV DNA, Scrape of Urogenital Epithelial Cells, 14 Types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) Screening)*	350
	(Candida albicans, DNA, Exudate)*	250
	(Candidiasis, Typing)	670
Susceptibility testing)	(Candida, Cryptococcus) (Yeast Culture. Identification and Antimycotic	690
	(Candidiasis, Screening)	360
Semen)*	(Candida albicans, DNA, Prostatic Fluid,	250
(Candida albicans, DNA, Scrape of Rectal Epithelial Cells)*		250
DNA, Scrape of Faucial Epithelial Cells)*	(Candida albicans,	250
Candida albicans, IgG (M5) (M5 Candida albicans, IgG)		520

	(Candidiasis, Screening and Typing)	920
A	IgG Candida albicans (Anti-Candida albicans IgG)	710
	(Candida albicans, DNA, Urine)*	250
	(Candida albicans, DNA, Scrape of Skin Epithelial Cells)*	250
	(Candida albicans, DNA, Scrape of Urogenital Epithelial Cells)*	250
	(Candida albicans, DNA, Saliva)*	250
:		
	()	1670
	(Upper Respiratory Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1980
	(Eye Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1340
	(Eye Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2240
	(Stool Culture with Bacteria Identification and Antibiotic+ Bacteriophage Susceptibility Testing)	1460
	(Stool Culture, Pathogenic Intestinal and Conditionally Pathogenic Microflora. Bacteria Identification and Antibiotic Susceptibility Testing)	1380
	(Breast Milk Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	980
	()	1570
	(Ear Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2240
	(Eye Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1160
	(Breast Milk Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1950
	(Punctate Fluid Culture. Bacteria Identification and Antibiotic Susceptibility Testing)	830
	(Wound/Pus/Aspirate/Tissue Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	980
	(Bile Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1040
	(Anaerobic Culture. Bacteria Identification and Antibiotic Susceptibility Testing)	1400
	(Sputum and Tracheobronchial washings Culture. Bacteria Identification and Antibiotic Susceptibility Testing, Microscopy)*	1080
	(Urine Culture. Bacteria Identification, Antibiotic susceptibility and Bacteriophage Efficiency Testing)*	980
A12.20.001		450
	(Ureaplasma spp. Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	680
	(Breast Milk Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	800
	(Genitourinary Tract Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2240
	(Wound/Pus/Aspirate/Tissue Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	800

(Mycoplasma hominis Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	770
(Genitourinary Tract Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1160
(Ear Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1340
(Urine Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1950
(Upper Respiratory Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1020
(Ear Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	1160
(Vaginal Biocenosis: Bacteriophage and Antimycotic Susceptibility Testing (Gram Stain, Bacterioscopic Examination of Smear))*	1500
(Wound/Pus/Aspirate/Tissue Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1950
(Bile Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	2150
(Breast Milk Culture. Bacteria Identification)	650
(Genitourinary Tract Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)*	1340
(Adenovirus), (Adenovirus. One Step Rapid Immun chromatographic Assay)	870
(Urine Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	800
(Sputum and Tracheobronchial washings Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing, Microscopy)*	2170
(Helicobacter pylori), (Helicobacter pylori. One Step Rapid Immun chromatographic Assay)	870
(Upper Respiratory Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*	830
(Punctate Fluid Culture. Bacteria Identification, Antibiotic Susceptibility, Enlarged Testing)*	1980
(Stool Culture, Pathogenic Intestinal and Conditionally Pathogenic Microflora, Bacteria Identification)	1190
6 ()	2180
1 ()	2180
12 () (Cobalamin)	630
(-) (Vitamin E, alpha-Tocopherol, Serum)	2180
5 ()	2180
1,25-D3 (1,25-dihydroxivitamin D3)	1900
3 ()	2180
25(OH)D2 25(OH)D3, (- /)	5460
(Folic Acid)	870
() (Vitamin A, Retinol, Serum)	2180
1 () (Vitamin K1, Phylloquinone, Serum)	2180
7, ()	2180
12 (, Active-B12, Holotranscobalamin)	1250

-		2180
2 ()		2180
()		2180
		2180
LGI1 CASPR2 (), IgG, (VGKC-associated proteins LGI1 and CASPR2 antibodies, serum)		5600
antibodies, IgG, Indirect immunofluorescence (IIF)	(Neuronal	3010
(Acetylcholine Receptor Antibodies, Anti-AChR, Total)	o	5210
IgG, NMDA, CASPR, LGI, AMPA1, AMPA2, GABAR1		12370
IgG () (Anti-Skeletal Muscle Antibodies, AStMA, IgG)		1110
NMDA, IgG, (-NMDAR IgG, N-methyl-D-Aspartate Receptor Antibodies, CSF)		2760
- IgG (- : Mi-2, Ku, PM-Scl 100/75; Jo1 PL-7 PL-12 EJ OJ; SRP, SSA (Ro52)) (Myositis-Specific Panel)		3670
IgG IgM (- : GM1; GM2-GM3-GM4; GD1a, GD1b, GD2-GD3, GT1a, GT1b, GQ1b,), (Anti-GM1 Antibodies, Anti-GQ1b Antibodies, Anti-Ganglioside antibodies, Ganglioside Antibodies Panel, Total)		5210
Criethidia luciliae, IgG, fluorescent test (CLIFT))	(Criethidia luciliae indirect	1150
IIF) IgG, (Anti-myelin antibody, IgG,		1340
IgA, IgG, IgM 4, () NMO) (Aquaporin-4 Receptor Antibodies, anti-AQP4, Neuromyelitis Optica, NMO, IgA, IgG, IgM, Total)		2600
IgG () (Oligoclonal IgG, Cerebrospinal Fluid (CSF), Serum)		3990
(Muscle-specific tyrosine kinase (MuSK) antibody)	(-MuSK)	4980
IgG, NMDA, CASPR, LGI, AMPA1, AMPA2, GABAR1		12500
LGI1 CASPR2 (), IgG, (VGKC-associated proteins LGI1 and CASPR2 antibodies, CSF)		5600
IgG, CSF) GAD (), IgG, (Anti-GAD (glutamic acid decarboxylase),		1890
(ANNA2),) (Anti-Neuronal Antibodies, Blot-Line (Hu (ANNA1), Yo-1 (PCA1), CV2, 2, Ri Ri (ANNA2), Amphiphysin))	IgG (- : Hu (ANNA1), Yo-1 (PCA1), CV2, 2, Ri	5210
IgG NMDA (N- -D-) (N-Methyl-D-Aspartate Receptor Antibodies IgG)		3990
Complement (CH50)) : (CH50) (Functionality Test of		1340
1- (C1-Esterase Inhibitor, 1-INH)		1960
4 (Complement Component C4)		360
3 (Complement Component C3)		360
IgG (Anti-Rubella IgG, Immunoblot)		5110
Ig (Anti-Rubella Ig)		490
Anti-Rubella IgG		970
(Rubella virus, RNA)		590
IgG (Anti-Rubella IgG)		360
B (B, Hepatitis B Virus, HBV)		
IgM IgG HB-core B, (Anti-HBc IgM, IgG, Antibodies to Hepatitis B Core Antigen; HBcAb, Total, HBV Core Total Antibodies (IgG + IgM))		470

HBs- « »), (HBs- , B, Quantitative) (HBsAg, Hepatitis Surface Antigen,	1320
HB - (Hepatitis Be Antigen, HBeAg)	510
IgM HB-core B (Anti-HBc IgM Antibodies to Hepatitis B Core Antigen; HBV Core Antibodies IgM)	630
B, (HBV DNA, Serum, Quantitative)*	3410
B, (HBV DNA, Serum, Qualitative)*	380
HBs- (Anti-HBs, HBsAb)	570
HB - (Anti-HBe, HBeAb)	470
HBs- (HBs- , B, « »), (HBsAg, Hepatitis Surface Antigen, Qualitative)	240
- 2 (2-Hour Oral Glucose Tolerance Test, OGTT, Glucose and C-Protein Concentration (Fasting and 2 Hours after Load), Venous Blood)	1390
A09.05.023	130
(Lactate)	520
(Fructosamine)	810
A09.05.083 HbA1 (HbA1 , Glycated Hemoglobin, GHb)	460
() Oral Glucose Tolerance Test, Plasma, OGTT, Pregnancy	900
A12.22.005 - 2 (2-Hour Oral Glucose Tolerance Test, OGTT, Glucose Concentration (Fasting and 2 Hours after Load), Venous Blood)	610
- () (C-Reactive Protein, CRP)	310
- (- ,) (Antistreptolysin-O, ASO)	340
-1- (1), (Alpha-1-Antitrypsin, A1AT, AAT, Phenotyping)	2360
(-) N- (NT-proBNP, N-Terminal Pro-brain Natriuretic Peptide, Pro-B-Type Natriuretic Peptide)	2560
(Ferritin)	460
- (Carbohydrate-Deficient Transferrin with results on an electrophoregram (CDT))	3020
25 () (Hepcidin 25, bioactive)	5970
(Heart Failure's biomarker)) ST2 (ST2, sST2,) (Soluble ST2)	2490
() (Transferrin)	440
(Myoglobin)	520
-2- (Alpha-2-Macroglobulin, ?2-Macroglobulin, A2M)	450
Pgp3 (IgG) Chlamydia trachomatis IgG	520
() (Rheumatoid Factor, RF)	340
-I (Troponin-I)	570
- ()	540
(Ceruloplasmin)	590
(Haptoglobin)	580
-1- (1), (Alpha-1-Antitrypsin, A1AT, AAT, Concentration)	1260
- (Carbohydrate-Deficient Transferrin, CDT)	2810
(, Soluble Transferrin Receptor, sTfR)	1700
(Eosinophil Cationic Protein, ECP)	790
() (Ureaplasma parvum), (Ureaplasma parvum, DNA, Urine)*	250

(Ureaplasma arzum), parvum, DNA, Prostatic Fluid, Semen)*	(Ureaplasma	250
IgG Ureaplasma urealyticum (anti-Ureaplasma urealyticum IgG)		610
(Ureaplasma urealyticum) (-960), (Ureaplasma urealyticum (T-960), DNA, Scrape of Urogenital Epithelial Cells)*		250
IgA Ureaplasma urealyticum (anti-Ureaplasma urealyticum IgA)		610
(Ureaplasma urealyticum + Ureaplasma arzum), (Ureaplasma urealyticum + Ureaplasma arzum, DNA, Prostatic Fluid, Semen)*		250
(Ureaplasma urealyticum + Ureaplasma arzum), (Ureaplasma urealyticum + Ureaplasma arzum, DNA, Urine)*		250
(Ureaplasma arzum), (Ureaplasma parvum, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Ureaplasma urealyticum) (-960), (Ureaplasma urealyticum (T-960), DNA, Prostatic Fluid, Semen)*		250
(Ureaplasma urealyticum + Ureaplasma arzum), (Ureaplasma urealyticum + Ureaplasma arzum, DNA, Scrape of Urogenital Epithelial Cells)*		250
(Ureaplasma urealyticum) (-960), (Ureaplasma urealyticum (T-960), DNA, Urine)*	(Ureaplasma	250
-		
A IgG (Anti-Respiratory Syncytial Virus (RSV) IgG)	-	710
A IgM (Anti-Respiratory Syncytial Virus (RSV) IgM)	-	710
-		
e (F2, F5) (Risk of Oral Contraceptives, Ocs (Genes F2, F5))		2730
e (F2, F5) () (Risk of Oral Contraceptives, OCs (Genes F2, F5) (without Description))		2450
, 6 (AZF) ()		3560
(MTHFR, MTRR, MTR, F2, F5) (Preparation for Surgery (Genes MTHFR, MTRR, MTR, F2, F5))		8010
(MTHFR, MTRR, MTR, F2, F5) () (Preparation for Surgery (Genes MTHFR, MTRR, MTR, F2, F5) (without Description))		7180
IgG:		
(F24), - IgG (Shrimp, IgG, F24)		520
(F9), - IgG (Rice, IgG, F9)		520
1: , IgG (FP15 (F33, F49, F92, F95), Food Panel: Orange, Banana, Apple, Peach, IgG)*		950
(F84), - IgG (Kiwi Fruit, IgG, F84)		520
(F11), - IgG (Buckwheat, IgG, F11)		520
(F3), - IgG (Codfish, IgG, F3)		520
3: , IgG (FP73 (F26, F27, F83, F88), Food Panel: Pork, Beef, Chicken Meat, Lamb, IgG)*		950
Food Profile, IgG) G (IgG) (Basic		14400
(F44), - IgG (Strawberry, IgG, F44)		520
(F7), - IgG (Oat, IgG, F7)		520
(F105), - IgG (Chocolate, IgG, F105)		520
(fx21) IgE, ImmunoCAP		1250
(F4), - IgG (Wheat, IgG, F4)		520
- , IgG (Beta Lactoglobulin, IgG, F77)		520
(F2), - IgG (Milk, IgG, F2)		520
(F25), - IgG (Tomato, IgG, F25)		520
(F55), - IgG (Common Millet, IgG, F55)		520
, IgG (Pineapple, IgG, F210)		520

	IgM Chlamydia trachomatis (Anti-Chlamydia trachomatis IgM)	510
	(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Rectal Epithelial Cells)*	250
	(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Urogenital Epithelial Cells)*	250
A	IgG Chlamydia trachomatis (Anti-Chlamydia trachomatis IgG)	490
	(Helicobacter pylori, DNA, Biopates of Gastric Mucosa and/or Duodenum, PCR)	2120
	(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Conjunctiva Epithelial Cells)*	250
A	IgA Chlamydophila pneumoniae (Anti-Chlamydophila pneumoniae IgA)	610
	(Chlamydia pneumoniae), (Chlamydophila pneumoniae, DNA, Sputum)*	790
A	IgM Chlamydophila pneumoniae (Anti-Chlamydophila pneumoniae IgM)	510
	(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Urine)*	250
	(Chlamydia trachomatis), trachomatis, DNA, Cerebrospinal Fluid)*	250
	(Chlamydia trachomatis), Exudate)*	250
	(Chlamydia trachomatis), trachomatis, DNA, Synovial Fluid)*	460
	(Chlamydia pneumoniae), (Chlamydophila pneumoniae, DNA, Scrape of Faucial Epithelial Cells)*	390
	(Chlamydia trachomatis), (Chlamydia trachomatis, DNA, Scrape of Faucial Epithelial Cells)*	250
	(Treponema pallidum, DNA, Prostatic Fluid, Semen)*	250
	(Treponema pallidum, DNA, Scrape of Urogenital Epithelial Cells)*	250
	(Treponema pallidum, DNA, Urine)*	250
	(Treponema pallidum, DNA, Cerebrospinal Fluid)*	250
	(Treponema pallidum, DNA, Serum)*	370
	(Treponema pallidum, DNA, Secretion)*	250
A	IgM IgG Treponema pallidum, (Anti-Treponema pallidum IgM, IgG, Total)	380
	(Treponema pallidum, DNA, Scrape of Skin Epithelial Cells)*	250
	(Treponema pallidum, DNA, Scrape of Faucial Epithelial Cells)*	250
A	IgG Treponema pallidum, (Anti-Treponema pallidum IgG, Immunoblot)	1790
	(Treponema pallidum, DNA, Scrape of Conjunctiva Epithelial Cells)*	250
A	IgM Treponema pallidum (Anti-Treponema pallidum IgM)	810
	RPR – (Syphilis RPR (Rapid Plasma Reagins), nticardiolipin est)	210
A	IgM Treponema pallidum, (Anti-Treponema pallidum IgM, Immunoblot)	1790
	(Testosterone)	350
	(-SO ₄ , Dehydroepiandrosterone sulfat, DHEA-S)	350
17-	(17-) (17-Ketosteroids, Urine)	1830
	() (Sex Hormone-Binding Globulin, SHBG)	360
	(Androstenedione)	1000
17-	(17-Hydroxyprogesterone, 17-OHP)	490
	(Free Testosterone)	870

() (Androstenediol Glucuronide, 3?-Androstenediol Glucuronid, 3?-diol G)	1050
() (Dih drotestosterone, DHT)	1300
()	
() (Protein, random urine, with creatinine and protein/creatinine ratio calculation)	260
(Magnesium, random urine, with creatinine and magnesium/creatinine ratio calculation)	530
-	280
() (Phosphorus, random urine, with creatinine and phosphorus/creatinine ratio calculation)	290
() (Oxalates, random urine, with creatinine and oxalate/creatinine ratio calculation)	1350
() (Albumin, random urine, with creatinine and albumin/creatinine ratio calculation, UACR)	450
(Calcium, random urine, with creatinine and calcium/creatinine ratio calculation)	200
(Urine Creatinine)	50
IgE:	
, IgE (Cockroach, IgE, I6)	440
, IgE (Dog Epithelium, IgE, E2)	440
, IgE (Sheep Epithelium, IgE, 81)	440
, IgE (Budgerigar Feathers, IgE, 78)	440
, IgE (EP70 (E6, E82, E84, E87, E88), Animal Panel: Guinea Pig Epithelium, Rabbit Epithelium, Hamster Epithelium, Rat, Mouse, IgE)*	950
, IgE (Guinea Pig Epithelium, IgE, 6)	440
, IgE (Cat Dander-Epithelium, IgE, E1)	440
, IgE (Chicken Feathers, IgE, 85)	440
- ()	
1 2 1 2 (HIV Ag/Ab Combo)	290
-1, (HIV RNA, Plasma)*	12940
(Everolimus)	3300
(Cyclosporine, Cyclosporine A, Sandimmune)	950
() (Teriflunomide, Leflunomide metabolite)	3300
(Levetiracetam, Keppra®)	3400
() (arbamazepine, Tegretol)	2620
(Mitotane, o, p?-DDD, plasma)	3300
() (Phenytoin)	1160
() (FK506, Advagraf, Prograf, Protopic, Tacrosel)	1430
(Lamotrigine)	3400
() (Acidum Valproicum, Depakin, Convulexs)	810
() (Phenobarbitalum)	2620
()	
Prostatic Fluid, Semen)* (Neisseria gonorrhoeae, DNA,	250
(Neisseria gonorrhoeae, DNA, Scrape of Rectal Epithelial Cells)*	250
Fluid)* (Neisseria gonorrhoeae, DNA, Synovial	460

(<i>Neisseria gonorrhoeae</i> ,), (GC, <i>Neisseria gonorrhoeae</i> Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		900
(<i>Neisseria gonorrhoeae</i> , DNA, Scrape of Conjunctiva Epithelial Cells)*		250
(<i>Neisseria gonorrhoeae</i> , DNA, Scrape of Faucial Epithelial Cells)*		250
(<i>Neisseria gonorrhoeae</i> , DNA, Urine)*		250
(<i>Neisseria gonorrhoeae</i> , DNA, Scrape of Urogenital Epithelial Cells)*		250
(<i>Lactobacillus</i> spp., DNA, Scrape of Urogenital Epithelial Cells)*		320
<i>Clostridium difficile</i> (Toxin A and B <i>Clostridium difficile</i> . One step rapid immunochromatographic assay)		1200
(<i>Clostridium difficile</i> ,) (<i>Clostridium difficile</i> Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		1250
()		1000
() (Cytological Examination: Cervix, Pap-test)		1000
IgE:		
/H1-Greer, IgE (House Dust - Greer, IgE, H1)		440
<i>Penicillium notatum</i> , IgE (<i>Penicillium notatum</i> , IgE, M1)		440
<i>Candida albicans</i> , IgE (<i>Candida albicans</i> , IgE, M5)		440
<i>Dermatophagoides pteronyssinus</i> (D1), IgE (<i>Dermatophagoides pteronyssinus</i> , IgE, D1)		440
<i>Aspergillus fumigatus</i> , IgE (<i>Aspergillus fumigatus</i> , IgE, M3)		440
<i>Alternaria tenuis</i> , IgE (<i>Alternaria tenuis</i> , IgE, M6)		440
<i>Dermatophagoides farinae</i> (D2), IgE (<i>Dermatophagoides farinae</i> , IgE, D2)		440
: <i>Penicillium notatum</i> , <i>Cladosporium herbarum</i> , <i>Aspergillus fumigatus</i> , <i>Candida albicans</i> , <i>Alternaria tenuis</i> , IgE (MP1 (M1, M2, M3, M5, M6), Mold Panel 1: <i>Penicillium notatum</i> , <i>Cladosporium herbarum</i> , <i>Aspergillus fumigatus</i> , <i>Candida albicans</i> , <i>Alternaria tenuis</i> , IgE)*		950
<i>Cladosporium herbarum</i> , IgE (<i>Cladosporium herbarum</i> , IgE, M2)		440
IgG:		
<i>Dermatophagoides farinae</i> (D2), - IgG (<i>Dermatophagoides farinae</i> , IgG, D2)		520
/Greer (1), - IgG (House Dust - Greer, IgG, H1)		520
<i>Cladosporium herbarum</i> (2), - IgG (<i>Cladosporium herbarum</i> , IgG, M2)		520
: <i>Penicillium notatum</i> , <i>Cladosporium herbarum</i> , <i>Aspergillus fumigatus</i> , <i>Candida albicans</i> , <i>Alternaria tenuis</i> , IgG (MP1 (M1, M2, M3, M5, M6), Mold Panel 1: <i>Penicillium notatum</i> , <i>Cladosporium herbarum</i> , <i>Aspergillus fumigatus</i> , <i>Candida albicans</i> , <i>Alternaria tenuis</i> , IgG)*		950
<i>Penicillium notatum</i> (1), - IgG (<i>Penicillium notatum</i> , IgG, M1)		520
<i>Dermatophagoides microceras</i> (D3), - IgG (<i>Dermatophagoides microceras</i> , IgG, D3)		520
<i>Dermatophagoides pteronyssinus</i> (D1), - IgG (<i>Dermatophagoides pteronyssinus</i> , IgG, D1)		520
<i>Alternaria tenuis</i> (6), - IgG (<i>Alternaria tenuis</i> , IgG, M6)		520
(AZF-) ((Impairment of Spermatogenesis: Full Panel (AZF-Region) (without Description))		9290
: (F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD) ((Want to Become a Mother: Pregnancy Complications (Genes F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD) (without Description))		15700
, CYP21A2, . . (Gene CYP21OHB, Freq. Mut.)		9790
: (F2, F5) (Thrombotic Tendency in Pregnancy: Minimum (Genes F2, F5))		2730

(AR, CFTR; AZF-) (Genetic Factors of Male Infertility (Genes AR, CFTR; AZF-Region))	16420
(MTHFR, MTRR, MTR) (Isolated Malformations in Fetus (Genes MTHFR, MTRR, MTR))	5280
(F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD) (Want to Become a Mother: Pregnancy Complications (Genes F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD))	18180
(MTHFR, MTRR, MTR, F2, F5) (() (Habitual Miscarriage, Thrombotic Tendency in Pregnancy: Extended Panel (Genes MTHFR, MTRR, MTR, F2, F5) (without Description))	7180
(F2, F5) ((without Description)) (Thrombotic Complications of Ovulation Induction (Genes F2, F5))	2450
(MTHFR, MTRR, MTR) ((without Description)) (Isolated Malformations in Fetus (Genes MTHFR, MTRR, MTR) (without Description))	4730
(ACE, AGT, MTHFR, MTRR, MTR, F2, F5) (Gestosis and Placental Insufficiency (Genes ACE, AGT, MTHFR, MTRR, MTR, F2, F5))	10610
(F2, F5) (Thrombotic Complications of Ovulation Induction (Genes F2, F5))	2730
(F2, F5) ((without Description)) (Thrombotic Tendency in Pregnancy: Minimum (Genes F2, F5) (without Description))	2450
(MTHFR, MTRR, MTR, F2, F5) (Habitual Miscarriage, Thrombotic Tendency in Pregnancy: Extended Panel (Genes MTHFR, MTRR, MTR, F2, F5))	8010
(ACE, AGT, MTHFR, MTRR, MTR, F2, F5) ((without Description)) (Gestosis and Placental Insufficiency (Genes ACE, AGT, MTHFR, MTRR, MTR, F2, F5) (without Description))	9440
/ BRCA1, BRCA2, CHEK2, NBS1 (Hereditary Breast and/or Ovarian Cancer)	9350
(Examination of Sputum)	750
(Examination of Transudates, Exudates, Secrets)	480
() (Examination of Bronchial Washouts)	590
(Examination of Punctates: Skin)	590
(Examination of Endoscopic Material)	590
A08.20.004	600
Helicobacter pylori (Examination of Endoscopic Material: Presence of Helicobacter pylori)	710
(Cytological Examination of Material Obtained during Surgical Procedures and Other Urgent Research)	750
(ThinPrep ®)*	1200
(The Bethesda System ? TBS) (Cytological Examination of Cervical Epithelium with Description on The Bethesda System, TBS)	570
() () (Cytological Examination: Scrapings (Smear) of Nasal Mucous Membrane (1 Localization))	710
(Examination of Breast Discharge)	480
(Examination of Punctates: Other Organs and Tissues)	750
() (Examination of Imprint Intrauterine Device, IUD)	510
(Examination of Punctates: Breast)	590
(Examination of Scrapings and Prints Tumor and Tumor Like Formations)	590
(Examination of Urine)	480
(The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), Fine-Needle Aspiration (FNA))	570

Scrapings and Prints of Skin and Mucous Membranes)	(Examination of	390
and Cervical Canal)	(Examination of Scrapings: Cervix	570
Ig	(Anti-Measles IgM)	710
IgG	(Anti-Measles IgG)	800
IgG	(Anti-Tick-borne Encephalitis Virus (TBEV)	480
(Detection of pathogen DNA/RNA in ticks: Tick-borne encephalitis Virus (TBEV), Borrelia burgdorferi s. l., Anaplasma Phagocytophilum, Ehrlichia muris/chafeensis (RNA/DNA), PCR)		3360
IgM	(Anti-Tick-borne Encephalitis Virus (TBEV)	610
(HPLC-MS/MS Organic Acids (Succinylate))		3590
HADHA (HADHA Gene, Freq. Mut. (Long-Chain 3-Hydroxyacyl-Coa Dehydrogenase (LCHAD) Deficiency))		5010
(Newborn Screening "HEEL")*		4990
(Biotin-Dependent Carboxylases Activity (Biotinidase Deficiency))		5010
GCDH (GCDH (Glutaryl-CoA Dehydrogenase) Gene, Freq. Mut. (Glutaric Aciduria, Type 1))		5010
(Analysis of the spectrum of organic urine acids by gas chromatography with mass spectrometry (GC / MS))		8300
ASS (ASS Gene, Freq. Mut. (Citrullinemia))		9530
GCDH (GCDH (Glutaryl-CoA Dehydrogenase) Gene (Glutaric Aciduria, Type 1))		40400
ACADM (ACADM Gene, Freq. Mut. (Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency))		5010
FAH (FAH Gene, Freq. Mut. (Tyrosinemia, Type 1))		8340
BTD (BTD (Biotinidase Deficiency) Gene, Freq. Mut.)		5010
FAH (FAH Gene (Tyrosinemia, Type 1))		49900
(OTC Gene (Ornithine Transcarbamylase (OTC) Deficiency))		38030
(Escherichia coli O157:H7, Culture. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)		1100
(Escherichia coli O157:H7, Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		930
(Escherichia coli O157:H7, Assay) (Escherichia coli O157:H7. One Step Rapid Immunochromatographic		930
1, (Human immunodeficiency virus, quality, RNA)		2470
19,		330
RHD (RHD gene of the fetus in the mother's blood)		5550
19,		330
19,		330

(Legionella pneumophila, One step rapid immunochromatographic assay, antigen, urine)	1440
(Respiratory Syncytial Virus, RSV, One step rapid immunochromatographic assay, antigen)	930
(Hexagon Chlamydia, One step rapid immunochromatographic assay, antigen)	1020
(Neisseria gonorrhoeae test, One step rapid immunochromatographic assay)	860
(Campylobacter spp., One step rapid immunochromatographic assay, antigen, stool)	1040
(Norwalk virus) - (Norwalk virus GI, GII, One step rapid immunochromatographic assay, antigen, stool)	1750
(Streptococcus pneumoniae, One step rapid immunochromatographic assay, antigen, urine)	1440
(Enterovirus, One step rapid immunochromatographic assay, antigen, stool)	1090
IgG -3 (Desmoglein 3, DSG3 Antibodies, IgG)	2160
IgG BP230 (Anti-Bp230 antibodies, Bullous Pemphigoid (230 kDa) Antibodies, Antibodies to BP Antigen 1, IgG)	2160
IgG BP180 (Anti-Bp180 antibodies, Bullous Pemphigoid (180 kDa) Antibodies, Antibodies to BP Antigen 2, IgG)	2160
IgG (Desmoglein Antibodies, Desmoglein 1, DSG1 and Desmoglein 3, DSG3 Antibodies, IgG)	2160
, IgG (Basement membrane zone antibodies, IgG)	2020
IgG -1 (Desmoglein 1, DSG1 Antibodies, IgG)	2160
A IgA Helicobacter pylori (Anti-Helicobacter pylori IgA)	700
A IgG Helicobacter pylori, (Anti-Helicobacter pylori IgG, Immunoblot)	3070
A IgA Helicobacter pylori, (Anti-Helicobacter pylori IgA, Immunoblot)	3070
A IgG Helicobacter pylori (Anti-Helicobacter pylori IgG)	490
1303HEL ?? - Helicobacter pylori (?? - , 13C-Urea Breath test, UBT).	2180
A IgM Helicobacter pylori (Anti-Helicobacter pylori IgM)	700
(Mycobacterium tuberculosis, DNA, Sputum)*	590
(Mycobacterium tuberculosis, DNA, Synovial Fluid)*	460
(Mycobacterium tuberculosis, DNA, Cerebrospinal Fluid)*	250
(Mycobacterium tuberculosis, DNA, Exudate)*	250
(Mycobacterium tuberculosis, DNA, Prostatic Fluid, Semen)*	250
IgM, IgA, IgG Mycobacterium tuberculosis, (Anti-Mycobacterium tuberculosis IgM, IgA, IgG, total)	1630
(Mycobacterium tuberculosis, DNA, Urine)*	250
(Mycobacterium tuberculosis, DNA, Serum)*	390
(Mycobacterium tuberculosis, DNA, Menstrual Blood)*	250
() (Circulating Immune Complexes (CIC))	1080
(Phagocytic Activity of Leucocytes)	1000
(Lymphocyte Activation Ability)	3450

CD4+ - , % (- , CD4+ T-cells, Percent and Absolute)		1370
(CD3+HLA-DR+, CD3-HLA DR+)* (Activated Lymphocyte: CD3+HLA-DR+, CD3-HLA DR+)*		1370
- , % (CD19+ , B-cells, Percent and Absolute)		1370
(Lymphocyte Phenotyping: CD3, CD4, CD8, CD19, CD16, CD56)		3450
G (IgG1, IgG2, IgG3, IgG4)		12510
IgM (Anti-Varicella-Zoster Virus IgM, Anti-VZV IgM)		780
Varicella-Zoster, (Varicella ZosterVirus, DNA, serum)		360
IgG (Anti-Varicella-Zoster Virus IgG, Anti-VZV IgG)		710
Varicella-Zoster, (Varicella Zoster Virus, DNA, scrape of faucial epithelial cells)		360
Varicella-Zoster, (VaricellaZosterVirus, DNA, saliva)		360
(Stool Culture, Salmonella s p., Shigella s p. Bacteria Identification, Antibiotic Susceptibility and Bacteriophage Efficiency Testing)		1150
Shigella flexneri 1-5 (Shigella flexneri 1-5, IHA)		440
(Stool Culture (Salmonella spp., Shigella spp.). Bacteria Identification)		780
Shigella sonnei (Shigella sonnei, IHA)		440
(Stool Culture (Salmonella spp., Shigella spp.). Bacteria Identification and Antibiotic Susceptibility Testing)		970
Shigella flexneri 6 (Shigella flexneri 6, IHA)		440
HER2/neu , HER2-) (HER2/neu Expression, HER2 Status, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))		4990
: - - - (P504S, AMACR), (34?E12), p63 (Prostate cancer – complex immunomorphological examination using assessment of the expression AMACR, high molecular weight cytokeratin (34?E12), p63)*		11400
() :) (Immunohistochemical diagnosis of lymphoproliferative diseases (Tissue Embedded in Paraffin Block))		25280
Ki-67 (MIB-1) , Ki-67 () (Ki-67 (MIB-1) Expression, Assessment of Proliferative Activity by Expression Ki-67, Immunohistochemical Study (Fixed Biomaterial in Formalin Buffer))*		5090
(CD138) () (Chronic Endometritis, Identification of Plasma Cells CD138, Immunohistochemical Diagnosis (Fixed Biomaterial in Paraffin Block))		5000
() :) (Immunohistochemical diagnosis of lymphoproliferative diseases (Fixed Biomaterial in Formalin Buffer))*		25280
() (Estrogen and Progesterone Receptors, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))		7140
: p16INK4a () (Early Diagnosis Marker of Dysplasia with High Risk Malignancy: p16INK4a, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))		4430
() :) (Immunohistochemical diagnosis in cancer metastasis of unknown primary origin (Tissue Embedded in Paraffin Block))		25280
(Estrogen and Progesterone Receptors, Immunohistochemical Study)*		6410

(P504S, AMACR), (34?E12), p63 (Prostate cancer – complex immunomorphological examination using assessment of the expression AMACR, high molecular weight cytokeratin (34?E12), p63)		11400
: p16INK4a () (Early Diagnosis Marker of Dysplasia with High Risk Malignancy: p16INK4a, Immunohistochemical Study (Fixed Biomaterial in Formalin Buffer))*		4430
HER2 in situ (FISH) (Determination of HER2 Status of Tumor, Fluorescence In Situ Hybridization)		29660
Ki-67 (MIB-1) , Ki-67 () (Ki-67 (MIB-1) Expression, Assessment of Proliferative Activity by Expression Ki-67, Immunohistochemical Study (Fixed Biomaterial in Paraffin Block))		5090
(CD138) () (Chronic Endometritis, Identification of Plasma Cells CD138, Immunohistochemical Diagnosis (Fixed Biomaterial in Formalin Buffer))*		5000
HER2/neu , HER2- () (HER2/neu Expression, HER2 Status, Immunohistochemical Study (Fixed Biomaterial in Formalin Buffer))*		4990
() () (Immunohistochemical diagnosis in cancer metastasis of unknown primary origin (Fixed Biomaterial in Formalin Buffer))*		25280
A09.05.065 ()		330
(T4 ,) (Total Thyroxine, TT4)		350
(3) (Free Triiodthyronine, FT3)		350
() (Anti-Thyroid Microsomal Antibodies)		500
A09.05.063 (4)		350
(- ,) (Anti- thyroid eroxidase utoantibodies, Antimicrosomal Antibodies, TPO Antibodies, TPOAb, Anti-TPO)		390
() (Thyroid-Stimulating Hormone Receptor Antibodies, TSH Receptor Antibodies, TSHRabs, TSH binding inhibitor immunoglobulin, TBI)		1400
(-) (Anti- thyroglobulin Autoantibodies, Thyroglobulin Antibodies, Tg Autoantibodies, TgAb, Anti-Tg Ab, ATG)		440
() (Thyroglobulin, TG)		630
() (Thyroid Uptake, T-Uptake, Thyroxine-Binding Capacity, TBC, Thyroxine-Binding Index, TBI, free T4 Index, fT4I)		510
(3) (Total Triiodthyronine, TT3)		350
SARS-CoV-2, (Coronavirus SARS-CoV-2 RNA detection in nasopharyngeal and oropharyngeal smear)		1390
: (Soil: Agrochemical Evaluation)*		9080
: (Soil: Comprehensive Toxicological Evaluation)*		19940
(,) (Growth Hormone, GH)		470
(,) (Adrenocorticotrophic Hormone, ACTH)		620
(1) (Somatomedin C, Insulin-like Growth Factor 1, IGF-1)		990
() (Luteinizing Hormone, LH)		350
(Macroprolactin)*		1080
(Prolactin)		350

() (Follicle Stimulating Hormone, FSH)		350
IgG (-ASGPR) (Autoantibodies Against Asialoglycoprotein Receptor, Anti-ASGPR, IgG)		1550
IgA, IgG, IgM (Anti-Mitochondrial Antibodies, AMA, IgA, IgG, IgM, Total)		1380
IgG (- 2, 2-3 , Sp100, PML, gp210, LKM-1, LC-1, SLA/LP, SSA/Ro-52), (Autoimmune Disease Liver Panel: AMA-M2, M2-3E (BPO), Sp100, PML, gp210, LKM-1, LC-1, SLA/LP, SSA/Ro-52, IgG, Immunoblotting)		3320
IgA+IgG+IgM (anti-liver kidney microsomal antibody, anti-LKM, IgG+IgM+ IgA)		1430
IgA, IgG, IgM (Smooth Muscle Antibodies, SMA, Anti-Smooth Muscle Antibodies, ASMA, IgA, IgG, IgM, Total)		1380
1-		
IgG (Insulin Autoantibodies, IAA, IgG)		610
(IA-2) (Islet Antigen 2 Antibodies, Anti-IA2 antibodies, IA-2 Ab, Tyrosine Phosphatase Antibodies)		1550
IgG (Anti-Islet Cell Antibodies, Islet Cell Autoantibodies, ICA)		1380
GAD/IA-2, (Anti-GAD/IA2 Antibodies Pool, Glutamic Acid Decarboxylase-65, GAD and Insulinoma Antigen 2 (Tyrosine Phosphatase, IA2, ICA-512) Autoantibodies, Total)		1550
IgG (-GAD) (Anti-GAD Antibodies, Glutamate Decarboxylase Antibodies, AT-GAD, IgG)		1590
(Yersinia enterocolitica, (Yersinia enterocolitica, Stool Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		1240
Yersinia enterocolitica :9 (Yersinia enterocolitica O:9, IHA)		440
IgG Yersinia enterocolitica (anti-Yersinia enterocolitica IgG)		490
IgA Yersinia enterocolitica (anti-Yersinia enterocolitica IgA)		490
Yersinia enterocolitica :3 (Yersinia enterocolitica O:3, IHA)		440
Yersinia pseudotuberculosis (Yersinia pseudotuberculosis IHA)		440
(F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1) (Extended Study of Hemostatic System (Genes F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1))		13650
(ITGB3) (-) (Platelet Fibrinogen Receptor (Gene ITGB3) (without Description))		1260
: (F2, F5, MTHFR, MTRR, MTR) (-) (Thrombosis: Advanced Panel (Genes F2, F5, MTHFR, MTRR, MTR) (without Description))		7180
ITGA2 .759 >T Hyperaggregation of platelets, gene polymorphism ITGA2 .759 >T		2760
: (F2, F5) (-) (Thrombosis: Minimum (Genes F2, F5) (without Description))		2450
(MTHFR, MTRR, MTR) (-) (Hyperhomocysteinemia (Genes MTHFR, MTRR, MTR) (without Description))		4730
ITGA2 .759 >T (-) Hyperaggregation of platelets, gene polymorphism ITGA2 .759 >T (without description)		2470
: (F2, F5) (Thrombosis: Minimum (Genes F2, F5))		2730
(MTHFR, MTRR, MTR) (Hyperhomocysteinemia (Genes MTHFR, MTRR, MTR))		5280
: (F2, F5, MTHFR, MTRR, MTR) (Thrombosis: Advanced Panel (Genes F2, F5, MTHFR, MTRR, MTR))		8010
(F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1) (-) (Extended Study of Hemostatic System (Genes F2, F5, MTHFR, MTR, MTRR, F13, FGB, ITGA2, ITG 3, F7, PAI-1) (without Description))		9450

Cerebrospinal Fluid)*	(Listeria monocytogenes, DNA,	230
	(Listeria monocytogenes, DNA, Urine)*	230
monocytogenes, DNA, Scrape of Nasal Epithelial Cells)*	(Listeria	210
(Listeria monocytogenes)	(Listeria monocytogenes Culture. Bacteria Identification and	690
Antibiotic Susceptibility testing)		
	(Listeria monocytogenes, DNA, Plasma)*	210
monocytogenes, DNA, Scrape of Faucial Epithelial Cells)*	(Listeria	210
Fluid)*	(Listeria monocytogenes, DNA, Synovial	460

IgE:

Vernal Grass, Perennial Rye Grass, Timothy Grass, Cultivated Rye Grass, Velvet Grass, IgE)*	, IgE (GP3 (G1, G5, G6, G12, G13), Grass Panel: Sweet	950
, IgE (Cottonwood, IgE, T14)		440
, IgE (Wormwood, IgE, W5)		440
, IgE (Timothy Grass, IgE, G6)		440
Common Ragweed, Mugwort, English Plantain, Lamb's Quarters, Russian Thistle, IgE)*	, IgE (WP1 (W1, W6, W9, W10, W11), Weed Panel:	950
, IgE (Birch, IgE, 3)		440
, IgE (Mugwort, IgE, W6)		440
T12, T3, T7), Tree Panel: Alder, Hazelnut, Willow, Birch, Oak, IgE)*	, IgE (TP9 (T2, T4,	950
, IgE (GP1 (G3, G4, G5, G6, G8), Grass Panel 1: Orchard Grass, Meadow Fescue,		950
Perennial Rye Grass, Timothy Grass, June Grass (Kentucky Bluegrass), IgE)*		

25-OH D (25-OH Vitamin D Total, 25(OH)D, 25-Hydroxycalciferol)		1920
() (Deoxyypyridinoline, DPD, Urine)		1250
(Gla) (steocalcin, N-Osteocalcin, Bone Gla Protein, BGP)		670
N- P1NP, Total) 1 (Procollagen Type 1 N-terminal Propeptide,		1360
(Carboxyterminal Cross-linking Teloepptide of Bone Collagen, Collagen Cross-linked C-Teloepptide,		870
Beta-Cross Laps, ?-CrossLaps Serum, C-Teloepptide, Crosslaps, Type 1 Collagen, , b- Tx Serum)		
(Human Cartilage Oligomeric Protein, COMP)		2450

(A B)

agalactiae), (Streptococcus group B, Streptococcus	(Streptococcus	880
agalactiae Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		
agalactiae) (Streptococcus agalactiae Culture. Bacteria Identification)	(Streptococcus group B, Streptococcus	690
Immun hromotographic Assay)	(Streptococcus Group B. One Step Rapid	1050
Step Rapid Immun hromotographic Assay)	() (Streptococcus Group A. One	870
pyogenes), (Streptococcus group A, Streptococcus	(Streptococcus	810
pyogenes Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		
, (Streptococcus spp., DNA, Saliva)*		390
pyogenes) (Streptococcus pyogenes Culture. Bacteria Identification)	(Streptococcus group A, Streptococcus	620
, (Streptococcus spp., DNA, Plasma)*		590
spp., DNA, Scrape of Faucial Epithelial Cells)*	(Streptococcus	390
, (Streptococcus spp., DNA, Sputum)*		790

A09.28.034.001 24-	(Metanephrines fractionated, free and conjugated , 24-h urine)	2260
	(Catecholamines and Serotonin Metabolites, 24 Hours-Urine: Vanillylmandelic Acid, V, 5-Hydroxyindoleacetic Acid, 5- I)	2260
	(Serotonin, Serum)	2090
	(Catecholamines: Epinephrine/Adrenaline, Norepinephrine/Noradrenaline, Dopamine, Urine)	2060
	(Catecholamines: Epinephrine/Adrenaline, Norepinephrine/Noradrenaline, Dopamine, Plasma)	2090
	(Histamine, Plasma)	2420
	(Metanephrines fractionated, free + conjugated, random urine)	1830
	(Catecholamines: Epinephrine/Adrenaline, Norepinephrine/Noradrenaline, Dopamine, Urine)	2060
(Opisthorchis felineus)		
	IgG (Anti-Opisthorchis felineus IgG)	790
(Giardia lamblia)		
	(Giardia lamblia. One Step Rapid Immunochromatographic Assay)	870
	IgM, IgG, IgA (Anti-Giardia lamblia IgM, IgG, IgA, Total)	570
()		
A09.28.027	(Amylase, 24-Hour or Timed Urine)	230
	(Ca), (Calcium (Ca), 24-Hour urine)	200
	(K), (Na), (Potassium (K), Sodium (Na), 24-Hour urine)	190
	(Glomerular Filtration Rate, GFR)*	190
A09.28.011	(Glucose, 24-Hour urine)	150
A09.28.009	(Urea, 24-Hour urine)	150
A09.28.010	(Uric acid, 24-Hour urine)	190
A09.28.003	(Protein Total, 24-Hour urine)	130
	(Magnesium, 24 h urine excretion)	300
		1890
	(Oxalates, 24-Hour urine)	1220
A09.28.003.001	(Albumin, 24-Hour urine)	320
A09.28.006	(Creatinine, 24-Hour urine)	150
	(P), (Phosphorus (P), 24-Hour urine)	200
(Immunoglobulin A, IgA)		
	(Immunoglobulin , Ig)	250
	G (Immunoglobulin G, IgG)	250
	E (IgE,) (Immunoglobulin Total, IgE Total)	390
(Glomerular Basement Membrane antibodies, anti-GBM, IgG)		
	(Anti-Neutrophil cytoplasmic antibodies, ANCA, IgG)	1220
	-3 (-PR-3) (Anti- proteinase-3 antibodies, PR-3- antibodies, PR-3 ANCA, IgG)	1120
	IgG, IgA, IgM 2 (PLA2R), (Anti-Phospholipase A2 Receptor Antibodies, Anti-PLA2R, IgG, IgA, IgM, Total)	2470
	(), IgG (Anti-Neutrophil Cytoplasmic Antibodies, ANCA, IgG, Panel)	3100

IgG C1q (Anti-Complement 1q Antibodies, Anti-C1q, IgG)		1120
IgG, IgA, IgM (Anti-Endothelial Cell Antibodies, AECA, IgG, IgA, IgM, Total)	(HUVEC),	1550
IgG (- PO) (Myeloperoxidase Antibody, MPO)		1120
1- 3- (Anti-Poliovirus serotypes 1, 3, IgG)		1450
b, IgG () (polyribosylribitolphosphate, PRP) (Haemophilus influenzae b (HiB), anti-PRP Haemophilus influenzae b IgG)	b	1810
A IgG Borrelia burgdorferi (Anti-Borrelia burgdorferi IgG)		570
Cerebrospinal Fluid)*	(orrelia burgdorferi, DNA,	460
Fluid)*	(orrelia burgdorferi, DNA, Synovial	460
A IgM Borrelia burgdorferi, burgdorferi IgM, Western Blot (WB))	- (Anti-Borrelia	1800
A IgG Borrelia burgdorferi, (Anti-Borrelia burgdorferi IgG, Immunoblot)		2020
A IgM Borrelia burgdorferi (Anti-Borrelia burgdorferi IgM)		570
(Barbiturates, Urine)*		1120
Substances Screening: Opiates, Amphetamines, Methamphetamine, Cocaine, Cannabinoids, Cannabinoid Metabolites, Urine)	? () (Drugs and Psychotropic	3100
() (Cannabinoids (Marijuana), Urine)*		1120
() (Ethanol (Alcohol) Urine)*		1120
« » () (;) (Pernicious Habits: Nicotine, Drugs, Psychostimulants and Psychotropic Substances, Urine)*		3280
(/) (Opiates (Morphine/Heroin), Urine)*		1120
- , (EBV DNA, Exudate)*		250
Fluid)*	(EBV DNA, Cerebrospinal	250
Antigens (VCA) IgG)	- (nti-EBV Viral Capsid	690
IgG)	- (nti-EBV Early Antigen (EA	570
(EBNA) IgG)	- (nti-EBV Nuclear Antigen	480
- , (EBV DNA, Blood)*		380
- , (EBV DNA, Saliva)*		250
Fluid, Semen)*	, (EBV DNA, Prostatic	250
(EBV DNA, Scrape of Nasal Epithelial Cells)*		250
(EBV DNA, Scrape of Urogenital Epithelial Cells)*		250
Ig Antigens (VCA) Ig)	- (nti-EBV Viral Capsid	480
DNA, Scrape of Faucial Epithelial Cells)*	(EBV	250
Serum)*	(EBV DNA,	370
- , (EBV DNA, Urine)*		250
- , (EBV DNA, Serum)*		380

IgE:		
2		1840
, IgE (Pediatric Panel, IgE)		3670
1		1840
, IgE (Respiratory Panel, IgE)		3670
, IgE (Panel Different Allergens, IgE)		3670
ImmunoCAP ISAC, 112 (Allergochip ImmunoCAP ISAC, 112 Allergic components)		27300
ALEX2, 300 IgE		26990
(MTHFR, MTRR, MTR) (-) (Folic Acid Metabolism (Genes MTHFR, MTRR, MTR) (without Description))		4730
: D (VDR) (-) (Osteoporosis, Vitamin D Receptor (VDR) (Gene VDR) (without Description))		1260
(MCM6) (Adult Lactase Deficiency (Gene MCM6))		1310
, I (HFE) (Hemochromatosis Type 1 (Gene HFE))		2600
: D (VDR) (Osteoporosis, Vitamin D Receptor (VDR) (Gene VDR))		1390
(UGT1A1) (Gilbert's Syndrome (Gene UGT1A1))		4540
: (CALCR, COL1A1) (-) (Osteoporosis: Abridged Panel (Genes CALCR, COL1A1) (without Description))		3630
(MTHFR, MTRR, MTR) (Folic Acid Metabolism (Genes MTHFR, MTRR, MTR))		5280
: (CALCR, COL1A1) (Osteoporosis: Abridged Panel (Genes CALCR, COL1A1))		4050
: (CALCR, COL1A1, VDR) (-) (Osteoporosis: Full Panel (Genes CALCR, COL1A1, VDR) (without Description))		4730
HLA II (DRB1, DQA1, DQB1) (Hereditary Predisposition to Diabetes Type 1 (Insulin-Dependent Diabetes), HLA Class II (Genes DRB1, DQA1, DQB1))		6240
: (CALCR, COL1A1, VDR) (Osteoporosis: Full Panel (Genes CALCR, COL1A1, VDR))		5280
-		
2 (118 / , 121 / , 123 / , 131 / , 141 / , 115 / , 124 / , 154 /) (Genetic Test Results: Description of the 2-nd Category Complexity)		1050
1 (7201 , 7611 , 7014 , 125 / , 7207) (Genetic Test Results: Description of the 1-st Category Complexity)		530
3 (122 / , 129 / , 120 / , 137 / , 138 / , 153 / , 110 / , 114 / , 140 / , 7661 , 7258 , 134 / , 135 / , 136 /) (Genetic Test Results: Description of the 3-rd Category Complexity)		2100
4 (144 / , 143 / , 139 / , 145 / , 108 / , 19 /) (Genetic Test Results: Description of the 4-th Category Complexity)		4730
(4)		
(Isoprinosine)		490
(Immunomax)		490
(Immunal)		490
(Thymogen)		490
(Panavir)		490
(Tactivinum)		490
(Imunofan)		490
(Polyoxidonium)		490
(Galavit)		490
(Imunorix)		490
(Licopid)		490
()		

IgG	oxoplasma gondii (Anti-Toxoplasma gondii IgG)	360
IgG	oxoplasma gondii (Anti-Toxoplasma gondii IgG)	490
	(Toxoplasma gondii, DNA, Serum)*	380
Cerebrospinal Fluid)*	(Toxoplasma gondii, DNA,	250
Anti-Toxopl gondii IgG		950
	(Toxoplasma gondii, DNA, Exudate)*	250
pneumoniae)	(Streptococcus	450
/	(Bordetella pertussis/parapertussis, Nasopharyngeal Culture. Bacteria Identification)	1440
(2) (Estradiol, E2)		350
(Progesterone)		350
() (Cortisol, Hydrocortisone)		350
A09.28.035 urine)	(Free Cortisol, Free Hydrocortisone, 24-Hour	690
(Aldosterone)		780
() (Direct Renin, Plasma)		830
(Cortisol, Saliva)		560
A09.05.230	(Cystatin C)	680
A09.05.017		150
A09.05.018	(Uric acid)	150
A09.05.020		150
-	p16INK4a Ki-67	5500
	(PLGF)	3600
(Inhibin B)		1120
MIS)	() (Anti-Mullerian Hormone, AMH, Mullerian Inhibiting Substance,	1120
-1-	() (Trophoblastic beta-1-Globulin, TBG)	440
IgG	V (Annexin V antibodies, aAnV, IgG)	1190
IgG	V (Annexin V antibodies, aAnV, IgG)	1190
IgG, IgA, IgM	-2- 1, (Anti-?-2-Glycoprotein 1 Antibodies, anti-?-2-G 1, IgG, IgA, IgM, Total)	1140
IgM IgG	(Anti-Phospholipid Antibodies, APA, IgM, IgG)	730
2	IgA	1090
IgG IgM	(Anti-phosphatidylserine/ prothrombin antibodies, Anti-PS/PT, IgG, IgM, Total)	1220
aCL, Screening)	(Anti-phospholipin Antibodies IgA, IgM, IgG,	1030
IgG IgM	(Anti-phosphatidylserine, IgG, IgM)	1620
2	IgM	1190
	(Anti-Phospholipid Antibodies Panel)	8190

IgA	(Anticardiolipin IgA, aCL IgA)	760
2	IgG	1090
IgG	(Anticardiolipin IgG, aCL IgG)	820
IgM	(Anticardiolipin IgM, aCL IgM)	1080
(Bile Acids)		
1	(Apolipoprotein A1, Apo A1)	2410
Cholesterol	(, , VLDL)	520
B	(Apolipoprotein B, Apo B)	370
A09.05.025	() (Triglycerides)	390
A09.05.004		190
(a), ()	(Lipoprotein (a), Lp (a))	200
A09.05.028		790
A09.05.026	() (Cholesterol Total)	150
()	Cholesterol LDL (direct)	190
(4)		
(Neovir)		230
(Amixin)		490
(Cycloferonum)		490
(Kagocel)		490
(Pregnancy-Associated Plasma		
Protein-A, PAPP-A)		630
HCG)	(, - , ?-) (Human Chorionic Gonadotropin,	350
Human Chorionic Gonadotropin, Free HCG)	(Free	490
PRISCA2		90
fms-	-1 (sFit-1)	3070
(Estriol Free, 3)		440
PRISCA1		120
Placental Lactogen, hPL, Chorionic Somatomammotropin, CS, Human Chorionic Somatomammotropin, hCS)	(Placental Lactogen, PL, Human	630
(Erythrocyte Sedimentation Rate, ESR)		
(130
« »	(Leucocyte Formula (Differential White Blood Cell Count) with Manual Microscopic Examination of Blood Smear)*	300
((Leucocyte Formula (Differential White Blood Cell Count) with Microscopic Examination of Blood Smear if Presence of Pathologic Changes)*	190
Microscopy (Manual Platelet Count (PLT Count): Indirect Method by Fonio)*	(Platelets,	250
without White Blood Cell (WBC) Count and ESR)	() (General Blood Analysis,	190
A12.05.123	(Reticulocytes)	240
(4)		
(Ingaron)		1800
(Reaferonum)		490

Bordetella species: Bordetella pertussis ()			
	Bordetella bronchiseptica ()	(Differentiated detection of DNA Bordetella spp.: Bordetella pertussis (pertussis pathogen) and Bordetella bronchiseptica (bronchosepticosis pathogen) in a scraping of the oropharynx and or nasopharynx)	840
A	IgG	Bordetella pertussis (Anti-Bordetella pertussis IgG)	810
A	IgM	Bordetella pertussis (Anti-Bordetella pertussis IgM)	810
A	IgA	Bordetella pertussis (Anti-Bordetella pertussis IgA)	810
-3 (Omega-3 Index)			
		(Procalcitonin)	2730
		, : -3,-6,-9, (Fatty acids panel, omega-3, -6, -9, plasma)	8340
		Rh- (Anti Rh)	470
A12.05.005		(Blood Group, O)	230
	Rh (C, E, c, e) Kell-	(Rh C (E, c, e) Kell-Phenotyping)	600
A12.05.006	-	(-) (Rh-factor, Rh)	230
		(Water: Complete and Comprehensive Quality Assessment)*	18180
		(Water: Suspicion Industrial Waste Contamination)*	12900
		(Water: Suspicion Products of Combustion and Emissions from Motorways Contamination)*	9530
		(Water: Suspicion Household Waste Contamination)*	8130
		(Water: Abridged Quality Assessment)*	8790
		(Water: Suspicion Excessive Use of Chemicals for Water Treatment)*	4690
(, Trichinella spiralis)			
	IgG	(nti-Trichinella IgG)	470
		20 (Water: Quality Assessment 20 Parameters)*	3730
		6 (Determination of Concentration 6 Radionuclides)*	22430
		- ?- (Radiological Drinking Water Study – Basic Test ?- and ?-Activity)*	6170
		30 (Water: Quality Assessment 30 Parameters)*	7060
		4 (Determination of Concentration 4 Radionuclides)*	14940
		(ACE, AGT, NOS3) (Arterial Hypertension: Full Panel (Genes ACE, AGT, NOS3))	4140
		(ACE, AGT, NOS3) ((Arterial Hypertension: Full Panel (Genes ACE, AGT, NOS3) (without Description))	3710
		(ACE, AGT) (Arterial Hypertension, Renin-Angiotensin System Disorder (Genes ACE, AGT))	2760
		(ACE, AGT) (-) (Arterial Hypertension, Renin-Angiotensin System Disorder (Genes ACE, AGT) (without Description))	2470
		(NOS3) (-) (Arterial Hypertension, Endothelial NO-Synthase Disturbance (Gene NOS3) (without Description))	1260
		() (Compositional Analysis of Urine (Kidney) Stones, infrared spectrometry)	3520

(Compositional Analysis of Urine (Kidney) Stones, infrared spectrometry, -ray diffraction analysis)		3520
(Alzheimer's Disease)		2600
Gastrin-17, G-17 (Gastrin-17 Stimulation Test, I (Pepsinogen I) (Gastrin) (GastroPanel) II (Pepsinogen II)		1100 880 620 4160 880
G, Hepatitis G Virus, HGV (HGV RNA, Serum)*		600
(FibroTest) (FibroMax) (FibroTest) (SteatoScreen) (FibroMax) NASH-FibroTest NASH-FibroTest ()		10860 13880 12200 5760 16000 17550 17120
() () (Karyotype) ()		7200 7090 16170
(Acute Intestinal Infections, PCR, Fecal) (Enterovirus, RNA, Fecal) (Acute Intestinal Infections, PCR, Fecal)		1430 470 1130
(beta-Adrenergic Blockers, Gene CYP2D6) ATII. (ACE) (ACE Inhibitors, Fluvastatin, ATII Receptor Blockers. (Methotrexatum. Genetic Markers of Increased Risk of Development of Adverse Reactions in Taking Methotrexate for Treatment of Rheumatoid Arthritis. Methotrexate Disrupts Metabolism		7390 2760 5280
A IgG (Anti-Mumps IgG) A IgM (Anti-Mumps IgM)		710 710
(Streptococcus pneumoniae, DNA)		450
(Calcitonin)		860

	() (Parathyroid Hormone, PTH)		610
	(, Echinococcus spp.)		
	IgG (Anti-Echinococcus IgG)		790
	IgG (Anti-Entamoeba histolytica IgG)		630
D	(D, Hepatitis D Virus, HDV)		
	IgM IgG D, o (Anti-HDV Total (IgG + IgM))		780
	D, (HDV RNA, Serum)*		600
	IgM D (nti-HDV IgM)		780
M3)	Aspergillus fumigatus (3), - IgG (Aspergillus fumigatus, IgG,		520
	(Bacteroides spp., DNA, Scrape of Urogenital Epithelial Cells)*		210
A	(, Hepatitis A Virus, HAV)		
	IgG (Anti-HAV IgG)		510
	(HAV RNA, Serum)*		590
	IgM (Anti-HAV IgM)		730
	()		
	(Gardnerella vaginalis, DNA, Scrape of Urogenital Epithelial Cells)*		250
	Prostatic Fluid, Semen)* (Gardnerella vaginalis, DNA,		250
	(Gardnerella vaginalis, DNA, Urine)*		250
	Converting Enzyme, ACE, Serum) () (Angiotensin		2200
	() (Neopterin, Serum)		1550
	IgG (Anti-Heart Antibodies, IgG) () ,		1220
	HOMA-G ()		50
	HOMA-IR		50
	(Proinsulin)		830
	(C-Peptide)		390
	(Insulin)		490
	Identification) (Campylobacter s p.) (Campylobacter spp., Stool Culture. Bacterial		1240
	()		
	(Rotavirus), (Rotavirus Direct Detection by Latex		680
	Agglutination)		
			3690
	(Varicella-Zoster)		
	Varicella-Zoster, (Varicella		360
	Zoster Virus, DNA, scrape of skin epithelial cells)		
	(-)		
		(Fungal Infections of Nails)	820
		(Fungal Infections of Skin)	820

	IgG	(Platelet antibodies IgG, Indirect)	2980
(, , , Salmonella spp.)			
	Salmonella gr.A	(Salmonella gr.A, IHA)	440
	Salmonella gr.B	(Salmonella gr.B, IHA)	440
	Salmonella gr.E,	(Salmonella gr.E Antibodies, IHA)	440
	Salmonella typhi,	(Salmonella typhi Antibodies, IHA)	560
	Salmonella O-	(Salmonella O-antigens, IHA)	440
	Salmonella gr.D	(Salmonella gr.D, IHA)	440
	Salmonella gr.	(Salmonella gr.C, IHA)	440
	IgG	(Anti-Strongyloides stercoralis IgG)	900
()			
		(Rickettsia prowazekii, IHA)	440
A09.05.021			150
A09.05.022			150
		Anisakis IgG	740
()			
	IgG	(Anti-Diphtheria Toxoid IgG)	900
		(Corynebacterium diphtheriae Culture)	690
		(Anti-Spermatozoa Antibodies, ASA, Semen)	1290
		(Anti-Spermatozoa Antibodies, ASA, Serum)	950
(E, Hepatitis E Virus, HEV)			
	IgM	E (Anti-HEV IgM)	810
	IgG	E (Anti-HEV IgG)	810
IgG:			
	(2), -	IgG (Dog Epithelium, IgG, E2)	520
	(1), -	IgG (Cat Dander-Epithelium, IgG, E1)	520
		(Streptococcus pneumoniae, DNA)	450
	IgG	(Anti-Adenovirus IgG)	710
	IgA	(Anti-Adenovirus IgA)	710
		(Streptococcus pneumoniae, DNA)	450
(, Toxocara canis)			
	IgG	(Anti-Toxocara IgG)	470
		(Androflor® REAL-TIME PCR Detection Kit, the study of men's urogenital tract microbiocenosis in the epithelial scrapes from the balanus, urethra)	2580
		(Androflor® Screen REAL-TIME PCR Detection Kit, the study of men's urogenital tract microbiocenosis in the epithelial scrapes from the balanus, urethra)	1810

(DLG5, NOD2, OCTN1, OCTN2) (Crohn's Disease (Genes DLG5, NOD2, OCTN1, OCTN2))		8090
IgA, IgM, IgG (Anti-Ovarian Antibodies, AOA, IgA, IgM, IgG, Total)		1290
IgA, IgM, IgG (Anti-Steroidal Cell Antibodies, StCAb, Steroidal Cell Autoantibodies, SCA, IgA, IgM, IgG, Total)		1120
IgA, IgM, IgG (Anti-Testicular Steroid-ell Antibodies, Testicular Anti-Steroidal Cell Antibodies, Testicular StCAb, Steroidal Cell Autoantibodies, SCA against Testis, IgA, IgM, IgG, Total)		1550
YP2D6 (YP2D6) (Cytochrome YP2D6 (Gene YP2D6))		7390
(Neisseria meningitidis Culture. Bacteria Identification and Antibiotic Susceptibility Testing)		850
() (Total Antioxidant Status, TAS)		4770
IgE: , IgE (Latex, IgG, K82)		440
IgG (Anti-Ascaris lumbricoides IgG)		880
(, Demodex folliculorum, Demodex brevis)		340
(Demodex folliculorum, Demodex brevis)		340
Cytological Preparations (1 Glass) () (Consultation of Finished		380
Clonorchis sinensis IgG		980
- 8 IgG 8 (Anti-HHV-8 IgG)		700
()*(Provision of test findings in English (translation of test findings in English)).*		200
(Erythropoetin)		960
(Leptin)		760
(Cryptosporidium parvum), (Cryptosporidium parvum. One Step Rapid Immun hromotographic Assay)		790
- IgG - 1 2 (Anti-HTLV-1, 2 IgG)		780
(Study of Interferon Status)		2450
(Assessment of Androgen Status)		1460
(Female Hormonal Profile: Ovarian Dysfunction, Menstrual Irregularities)		3300
(Female Hormonal Profile: Ovarian Dysfunction, Menstrual Irregularities)		3420
		3190
		3520

	6410
« »	7500
« »	9060
« »	15710
-	19010
() (Acute Respiratory Infections, ARI: Runny Nose, Cough, Sore Throat)	7390
A IgA IgG Chlamydia trachomatis, (Anti-Chlamydia trachomatis IgA, IgG)	970
« : 6 ()» (Comprehensive Study «Sex in City: 6 Infections (Blood Test)»)	3150
« : 6 ()» (Comprehensive Study «Sex in City: 6 Infections (Blood Test)»)	3270
: (Joint Pain: Extended Survey)	6780
: (Want to Become a Mother: Pregnancy Planning, Comprehensive Survey)	6990
VIP- (VIP-Survey for Men)	7240
VIP- (VIP-Survey for Women)	14790
(Pediatric Infections: Immune Response)	15700
A IgM IgG Mycoplasma pneumoniae (Anti-Mycoplasma pneumoniae IgM, IgG)	5440
TORCH- (ToRCH-Infections)	990
: I (1-13) (Pregnancy: First Trimester (1-13 Weeks))	3240
(HIV, Syphilis, Hepatitis B, C)	7480
« : 8 + » (Comprehensive Study «Sex in City: 8 Infections + Smear on Flora»)	1400
: III (29-30) (Pregnancy: Third Trimester (29-30 Weeks))	2540
« : 14 + » (Comprehensive Study «Sex in City: 14 Infections + Smear on Flora»)	3630
:	4010
() (Hemostasiogram (coagulogram), extended)	9930
: (Survey of Liver: Extended)	2510
(Hospitalization in Therapeutic Hospital)	2630
(Hospitalization in Surgical Hospital)	3330
: (Hospitalization in Surgical Hospital: Extended Survey)	4600
« » (My Healthy Nurse)	6720
ROMA (Risk of Ovarian Malignancy Algorithm,) (Risk of Ovarian Malignancy Algorithm, ROMA (Before Menopause))	7020
ROMA (Risk of Ovarian Malignancy Algorithm,) (Risk of Ovarian Malignancy Algorithm, ROMA (After Menopause))	1650
-) (Breast Cancer, Immunohistochemistry, IHC (Formalin-Fixed Biomaterial))	1650
-) (Breast Cancer, Immunohistochemistry, IHC (Paraffin-Embedded Tissue Block))	15660
- : p16INK4a + Ki-67 () (Cervical Cancer – Study of Two Markers for Early Diagnosis Dysplasia with High Risk Malignancy: p16INK4a + Ki-67, Immunohistochemical Screening (Fixed Biomaterial in Paraffin Block))	15660
- : p16INK4a + Ki-67 () (Cervical Cancer – Study of Two Markers for Early Diagnosis Dysplasia with High Risk Malignancy: p16INK4a + Ki-67, Immunohistochemical Screening (Fixed Biomaterial in Formalin Buffer))*	7830
- : p16INK4a + Ki-67 () (Cervical Cancer – Study of Two Markers for Early Diagnosis Dysplasia with High Risk Malignancy: p16INK4a + Ki-67, Immunohistochemical Screening (Fixed Biomaterial in Formalin Buffer))*	7830

(Metabolic bone and osteoporosis risk evaluation: comprehensive examination).	5360
: I (PRIS A-1) (Maternal Screen, First Trimester; Prenatal Screening I; PRIS A I (Prenatal Risk Calculation))	1170
: II (PRIS A-2) (Maternal Screen, Second Trimester; Prenatal Screening II; PRISCA II (Prenatal Risk Calculation))	1300
B03.005.006 (), (Coagulation, Gemostaziogram, Screening)	770
: (Miscarriage: Autoimmune Profile)	3640
(Immunological Survey Extended)	10980
: (Survey of Liver: Screening)	840
B03.016.004 :	1100
Supersport	2000
: (Serum Biochemistry: Minimum)	2020
Supersport	3100
: (Serum Biochemistry: Extended Profile)	3230
- : (40) (Healthy You ? Healthy Country: Annual Check-Up up to 40 Years of Age)	3510
(40) (Annual Check-Up after 40 Years of Age)	4480
: (Survey Before Diet: Additional)	4690
Supersport	6830
	3690
: (Survey of Kidneys: Extended)	2000
: (Diabetes Control: Extended)	3220
(Toxic Trace Elements, Hair)	1620
(Toxic Trace Elements, Essential Vital Elements, Hair)	3090
(Elemental Composition of Hair: Screening)	5400
() (Essential Vital Elements, Toxic Trace Elements, Urine)	2600
(Toxic Trace Elements, Nails)	1620
(Toxic Trace Elements, Essential Vital Elements, Nails)	3090
(Elemental Composition of Nails: Screening)	5400
	24050
	24050
	24050
	24050
	24050
	24050
	33000
(Testing for Kindergarten and School)	1580
: 0 14 (Healthy Child: for Children from 0 to 14 Years)	660
: (Survey of Kidneys: Screening)	870
	890
	18500
	17400
	17400
(Panel Chronic myelogenous leukemia, CML)	11900
	33000
	11100
	3150

	2210
(, ())	2160
()	2160
(/pANCA, cANCA), IgG)	2250
(, , IgG, IgM)	2890
(, (), /pANCA, cANCA), IgG)	3730
(, IgG;	3950
(;	3970
, IgG, IgM; -2- 1)	4620
: (Arthralgia: screening test)	6380
(Autoimmune Liver Disease: Screening)	1670
(Rheumatic arthritises)	1690
SARS-CoV-2, IgM () IgG (Anti-SARS-CoV-2, IgM/IgG)	3970
« » (Bullous Dermatitis Diagnostics profile (antibodies to epidermis desmosomes, antibodies to skin basal membrane))	1290
SARS-CoV-2, IgM IgG (Abbott)	1690
SARS-CoV-2, IgM () IgG (Anti-SARS-CoV-2, IgM/IgG)	1690
: (Thyroid Gland: Extended Survey)	1760
: (Thyroid Gland: Extended Survey)	1010
: (Thyroid Gland: Screening)	3560
: (Diabetes: Autoimmune Markers)	2810
(Rheumatoid arthritis).	830
Ig IgG Mycoplasma hominis (nti-Mycoplasma hominis Ig , IgG)	2640
(/pANCA, cANCA), IgG)	2730
;)	1220
4 « » (Systemic lupus erythematosus (SLE) profile, activity monitoring (anti-double-stranded DNA IgG, C3 and C4 complement components))	1970
, IgG; IgA) (, IgA;	5660
Intolerance) () (Coeliac Disease: Gluten	1800
, IgG, IgM	3570
APS) (), (Antiphospholipid Syndrome,	4340
cANCA, IgG; /ANCA, IgA; ASCA, IgG, IgA) () (/pANCA,	2470
(,)	3230
IgA, IgG; IgA) (, IgA;	2690
steroid-producing cells Antibodies) (Reproductive tissue	8150
(Food Allergy)	2640
: (Lipid Profile: Extended)	2640
: (Lipid Profile: Extended)	4510
" / " IgE, ImmunoCAP	4510
" " IgE, ImmunoCAP	1390
(NOS3) (Arterial Hypertension, Endothelial NO-Synthase Disturbance (Gene NOS3))	

" / " IgE, ImmunoCAP	4510
« : 12 + ()» (Comprehensive Study «Sex in City: 12 Infections (Urogenital Scraping)»)	2630
	1290
-	1460
*	4100
	11760
	720
(Diagnosis of Anemia)	2890
(Diagnosis of Anemia)	3200
(Preventing Heart and Blood Vessel Diseases)	2820
: (Pregnancy Planning: Diagnosis of Urogenital Tract Infection (UTI))	2260
: (Diabetes Control: Screening)	560
: (Survey Before Diet: Minimum)	1560
(Problems: Primary Survey)) (Weight	2930
(Healthy skin beauty)	1260
:	590
HOMA-IR (Insulin Resistance: Fasting Glucose/Insulin, Homeostasis Model Assessment of Insulin Resistance, HOMA-IR)	670
" : () ()" : ()	860
(Weight Problems: Metabolic Syndrome (Primary Identification, screening)	
(Diagnosis of Osteoporosis)	2770
: (Women's Oncorisk: Cervix)	1800
, , (Allergy to Animals, Dust, Mold)	5780
:	1500
, , (Strong hair and nails, velvet skin)	3150
: (Trace Elements, Serum, Venous Blood: Screening)	3070
(Mold Allergy)	2010
(Plant Allergy)	4380
(Immunological Survey, Screening)	6400
(AR, CFTR; AZF- ;) (Male Sterility (Genes AR, CFTR; AZF-Region; Karyotype))	21360
(F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD, HLA II;) (Female Infertility, Pregnancy Complication (Genes F2, F5, MTHFR, MTRR, MTR, ACE, AGT, RHD, HLA II; Karyotype))	25940
(e) (Toxic Trace Elements, Toxic Heavy Metals, Venous Blood)	1250
- , (,)	2150
(, , , ,)	2040
	160
CKD-EPI – (Estimated Glomerular Filtration Rate, eGFR, CKD-EPI Creatinine Equation)	160
B03.016.003 ()	420
: II (14-28) (Pregnancy: Second Trimester (14-28 Weeks))	760

ESR (with Manual Microscopic Examination of Blood Smear)		590
(Essential Vital Elements, Essential Trace Elements, Serum)		1250
disorders (6 AZF)	(AZF-) (Impairment of	4610
Spermatogenesis: Full Panel (AZF-Region))		10370
IgG ()		5300
(DQA1, DQB1)	HLA II	6240
(RH factor Genotype)		9910
(skin)	() (Parasitic Fungi, Microscopy and Culture	1570
(nails)	() (Parasitic Fungi, Microscopy and Culture	1570
I/Pepsinogen II, PG1/PG2)	(I/ II) (Pepsinogen	1820
: sFlt-1, PlGF,	sFlt-1/PlGF	5880
(Mycoplasma hominis Culture, Ureaplasma spp. Culture. Bacteria Identification and Antibiotic Susceptibility Testing)*		1350
:	(Male oncologic risk: prostate)	870
-	(Aldosterone-Renin Ratio, ARR)	1280
	3, 4 (Complement components C3, C4)	720
"	", IgE, ImmunoCAP	2120
B03.016.005	: (Lipid Profile: Screening)	700
	(ITGB3) (Platelet Fibrinogen Receptor (Gene ITGB3))	1390
:	(Lipid Profile: Screening)	700
Filtration Rate, eGFR, CKD-EPI -	(Estimated Glomerular	720
ystatin C Equation)		
TREC	KREC	4830
19.1	29 28.01.2021 . . .	10500
() . 5.1; . 5.2; . 19.1	29 28.01.2021 .	15000
(, 40) . 5.1; . 5.2; . 19.1	29 28.01.2021 .	12070
(, 40) . 5.1; . 5.2; . 19.1	29 28.01.2021 .	11570
/		2000
		230
(10)		440
125 (40)		580
()		150
()		150
()		450
()		950
		775.84

()
()
(40)
()
()
()
()

950
1800
1000
1500
2000
2100
100
273.29
172.59
143.14
287.54
2120
1013.34
2120
1500
700
800
1500
2600
2600
3100
3100
4000
3500